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Abstract
Focused ultrasound is currently being developed as a non-invasive thermal ablation
technique for benign and cancerous tumors in several organ systems. Although these therapies
are designed to ablate tissue purely by thermal means, cavitation, the formation and collapse of
gas bubbles, can occur. These bubbles can be unpredictable in their timing and location and often
interfere with thermal therapies. Therefore, focused ultrasound techniques have tried to avoid
bubbles and their effects. However, gas bubbles in vivo have some potential useful features for
therapy. They greatly enhance local ultrasound absorption, and can on their own induce
mechanical damage to the tissue. In addition, bubble clouds can block ultrasound wave
propagation, providing a means to protect vital tissues during ablation of nearby pathology. If
induced and controlled properly, cavitation in focused ultrasound therapy could potentially be
very beneficial.
The first aim of this research is to design and test in vivo ultrasound exposures that
induce cavitation at appropriate times and take advantage of their absorption enhancing
properties. In addition, methods to monitor and control cavitation induction and the associated
therapy will be investigated. Second, a theoretical bubble model and acoustic field simulations
will be used to design optimal pressure fields which very tightly control the cavitation location.
These models will also be used to investigate methods for reducing the acoustic powers needed
to induce cavitation while preventing off focus cavitation. For the final phase of the research a
multi-channel, multi-frequency ultrasound amplifier system capable of delivering optimal
exposures via large scale phased array systems will be developed and tested. In total, the thesis
research will justify applications for cavitation in ultrasound therapy, and develop the technology
and methodology to optimally use cavitation and monitor its effects in vivo.
Thesis Supervisor: Kullervo Hynyen, Ph.D.
Title: Professor of Radiology, Harvard Medical School, Brigham & Women's Hospital
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1 Introduction
1.1 Background
In medicine, various device-based interventional techniques have been investigated to induce
morphological tissue changes as non-invasive or minimally invasive alternatives to surgery.
Radiation therapy has probably been the most successful device-based intervention to date as it is
used widely to kill proliferating cancer cells. However, side effects of radiation both to patients and
practioners, and the inability to appropriately focus the radiation-induced damage limit its
potential. Among the most promising alternatives to ionizing radiation-based interventions are
thermal techniques. Devices for thermal therapy include ultrasound transducers, lasers, and
antennas operating at microwave or RF frequencies. These techniques aim to create local bioeffects
(structural or functional changes) in a target area (typically tumors or malfunctioning tissue) while
leaving the surrounding healthy tissues unharmed. The induced temperature rise can be high
enough (thermal ablation) to cause coagulative necrosis, protein denaturization-based cell death, or
just a few degrees for an extended period of time (hyperthermia) to sensitize the tissue for adjuvant
radiation or chemotherapy. These techniques can be highly localized, they can be applied as
minimally invasive or non- invasive procedures, and they do not use harmful ionizing radiation.
These properties offer obvious advantages over standard surgical, radiation, and even
chemotherapy treatments and procedures.
Of all of these interventional techniques, ultrasound is unmatched in its flexibility and its
potential for use in several applications. At therapeutic frequencies, 0.5 to 4 MHz, ultrasound can
be tightly focused (on the order of the wavelength) with very little power deposition in the near
field. A typical ultrasound wave at 1.0 MHz has a wavelength of 1.5 mm and a penetration depth
of roughly 10 cm (Hynynen & Lulu 1990) in soft tissue. In comparison, a microwave, which
radiates at 2450 MHz has a wavelength of 1.8 cm and a penetration depth of only 1.7 cm in tissue
(Johnson 1972). Therefore ultrasound applicators can be extracorporeal devices for noninvasive
treatment. However, for difficult to access tissues, ultrasound applicators can be outfitted in
interstitial probes (Diederich et al. 2000;Hynynen & Davis 1993;Lafon et al. 1998), intracavitary
applicators (Foster et al. 1993;Hutchinson & Hynynen 1996;Sokka & Hynynen 2000), or
intravascular catheters (Hynynen et al. 1997;Zimmer et al. 1995). Ultrasound propagates and
interacts with tissue as a mechanical wave; therefore, bioeffects that are mechanical in nature, not
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just thermal, can be induced distinguishing it from all the electromagnetic radiation techniques.
These mechanical effects produced in vivo by high intensity ultrasound can be used therapeutically.
Ultrasound with its mechanical and thermal effects, has been investigated for several medical
applications by several researchers including tumor ablation (Adams et al. 1996;Chen et al.
1993;Chen et al. 1998;Chen et al. 1999b;Fry et al. 1978;Goss 1984;Prat et al. 1995;Rowland et al.
1997;Sibille et al. 1993;ter Haar et al. 1991;Vaezy et al. 2000;Yang et al. 1991;Yang et al.
1992;Yang et al. 1993), vessel occlusion (Delon-Martin et al. 1995;Hynynen et al. 1996b;Rivens et
al. 1999), hemostasis (Vaezy et al. 1997;Vaezy et al. 1998), thrombolysis (Francis et al.
1992;Porter et al. 1996), drug delivery (Unger et al. 1998), gene therapy (Greenleaf et al.
1998;Huber & Pfisterer 2000;Kim et al. 1996;Lawrie et al. 2000;Madio et al. 1998;Miller et al.
1999;Unger, McCreery, & Sweitzer 1997), focal opening of the blood brain barrier (Hynynen et al.
2001a;Vykhodtseva, Hynynen, & Damianou 1994), and direct mechanical damage with cavitation
(Miller et al. 2000;Prat et al. 1994b;Vykhodtseva, Hynynen, & Damianou 1994). Non-thermal
mechanisms such as cavitation, acoustic streaming (Frizzell, Miller, & Nyborg 1986), radiation
pressure (Dalecki et al. 1997), and cavitation microstreaming (Miller 1987), are also being
investigated as potential cellular level interventions. All of these investigations show the utility of a
particular ultrasound bioeffect for a particular application, but which bioeffect occurs in tissue for a
given ultrasound exposure is still highly variable. With advances in ultrasound phased array
systems (Benkeser et al. 1987;Buchanan & Hynynen 1994;Cain & Umemura 1986;Clement et al.
2000a;Curiel et al. 1999;Daum et al. 1999a;Diederich & Hynynen 1989;Do-Huu & Hartemann
1981;Ebbini et al.. 1988;Ebbini & Cain 1991a;Ebbini & Cain 1991b;Fan & Hynynen 1995;Fjield &
Hynynen 1997;Frizzell et al. 1985;Hutchinson & Hynynen 1998;Hynynen et al. 1996a;Hynynen &
Jolesz 1998;Ibbini & Cain 1990;McGough et al. 1994;McGough, Ebbini, & Cain 1992;Ocheltree
et al. 1984;Sokka & Hynynen 2000;Umemura & Cain 1989;VanBaren et al. 1995), precise control
of the type of bioeffect, mechanical, thermal or both, with precise control of the shape and
distribution of the acoustic and temperature fields seems feasible. Such control, which would allow
selection of the ultrasound bioeffect in space and time, should dynamically enhance the clinical
future of therapeutic ultrasound. The primary focus of this thesis is to show that this control of the
two major ultrasound bioeffects, cavitation and thermal effects, is indeed possible and
advantageous.
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1.2 History
As early as the 1920s and 30s, investigators, encouraged by the potential of X-ray therapy of
cancers, explored ultrasound as a treatment modality even before it was considered for diagnostics
(Nakahara & Kabayashi 1934;Szent-Gorgyi 1933;Wood & Loomis 1927). The initial studies
showed mixed results as some trials even demonstrated that ultrasound induced cancer growth. In
1935, Gruetzmacher demonstrated that an ultrasound beam could be focused (Gruetzmacher 1935),
and in 1942, Lynn first proposed the use of focused ultrasound for therapy (Lynn et al. 1942). In
the 1940s to 1960s, the Fry brothers, Francis and William, demonstrated the concept of focused
ultrasound surgery by treating patients with brain disorders (Barnard et al. 1956;Fry et al. 1950;Fry
1954;Fry et al. 1955;Fry, Barnard, & Fry 1955;Fry, Brennan, & Barnard 1957). During this time,
the exact mechanisms of the ultrasound-induced bioeffect were hotly debated. In the 1960's and
70's, Padmaker Lele demonstrated with numerous in vivo studies in small animals that thermal
effects resulting from ultrasound absorption (Basauri & Lele 1962;Lele 1962;Lele 1967;Lele
1975;Lele & Pierce 1973) could explain most tissue damage resulting from high intensity focused
ultrasound. Although significant understanding of the focused ultrasound therapy was gained
during these early works, many factors still limited Focused Ultrasound Surgery (FUS) from
becoming an accepted clinical therapy. Early ultrasound treatments lacked appropriate visual and
thermal feedback, which made focusing the ultrasound at the desired location, monitoring thermal
dose during treatment, and post treatment assessment extremely difficult. Some of these
investigations used x-ray or ultrasound guidance for aiming the ultrasound beam, and either no
monitoring of the induced temperature or tissue changes or only selective point monitoring with
invasive temperature probes (Fry 1970;Fry 1968;Fry 1971). In addition, ultrasound hardware (the
transducers and driving systems) was not advanced enough to provide adequate acoustic and
temperature field control. Despite the technological shortcomings, numerous clinical studies with
high intensity ultrasound showing the enormous promise of the technology have been performed in
various organs, including the prostate (Beerlage et al. 1999;Bihrle et al. 1994;Chapelon et al.
1999;Chaussy & Thuroff 2000;Eberle et al. 1996;Ebert et al. 1995;Foster, Bihrle, Sanghvi, Fry, &
Donohue 1993;Gelet et al. 1999;Gelet et al. 2000;Kiel, Wieland, & Rossler 2000;Madersbacher et
al. 1998;Madersbacher et al. 2000;Mulligan et al. 1997;Nakamura et al. 1995;Nakamura et al.
1997;Sanghvi et al. 1996;Sanghvi et al. 1999;Sullivan et al. 1999;Sullivan et al. 1997;ter Haar et al.
1998;Uchida et al. 1995;Vallancien et al. 1992;van Leenders et al. 2000), liver (ter Haar, Rivens,
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Moskovic, & Huddart 1998;Vallancien, Harouni, Veillon, Mombet, Prapotnich, Bisset, &
Bougaran 1992), bladder (Vallancien et al. 1996;Watkin et al. 1996), breast (Hynynen et al.
2001c), testis (Madersbacher, Kratzik, Susani, Pedevilla, & Marberger 1998), kidney (ter Haar,
Rivens, Moskovic, & Huddart 1998;Vallancien, Harouni, Veillon, Mombet, Prapotnich, Bisset, &
Bougaran 1992), and eye (Coleman et al. 1985). Recently, treatments of various targets with FUS
surgery in more than 1, 000 patients in China have been reported ( 2001).
1.3 Notable Recent Technological Advances
Technologies for improving FUS have advanced on both the image guidance and the
acoustic field control fronts and are now entering the clinical investigation phase. Visualization
techniques for localizing the diseased tissue and then monitoring temperatures during treatment
have evolved only recently. Several investigators have used ultrasonography for guidance (Fry et
al. 1968;Madersbacher et al. 1995;Sanghvi, Foster, Bihrle, Casey, Uchida, Phillips, Syrus, Zaitsev,
Marich, & Fry 1999;Sheljaskov et al. 1997), but ultrasound thermometry is complicated by multi-
parameter dependence on temperature. Others have used CT for both focus localization and
thermometry (Fallone, Moran, & Podgorsak 1982;Jenne et al. 1997), but ionizing radiation limits
CT's acceptability for real-time monitoring. MRI has established itself as the optimal imaging
modality as both guidance and thermometry with high spatial and temporal resolution is possible.
MRI provides excellent soft tissue contrast for diseased tissue segmentation, while temperature
sensitive pulse sequences can be used to measure relative temperature changes with an accuracy of
±0.5°C with time resolution of a few seconds (Chung et al. 1996;Ishihara et al. 1992;Samulski et
al. 1992). Several studies have shown the feasibility of MRI-guided ultrasound surgery in vivo
animal models (Cline et al. 1995;Hynynen et al. 1996c;McDannold et al. 1998;Parker
1984;Stepanow et al. 1995), and more recent work has shown that MRI thermal dosimetry
techniques can be used to accurately predict the extent of thermal tissue damage (Chung, Jolesz, &
Hynynen 1999;Hazle et al. 2002).
Therapeutic ultrasound hardware has also evolved dramatically over the past two decades,
mainly with the advent of phased array transducers. Ultrasonic phased arrays consist of multiple
ultrasonic generators, piezoelectric elements, arranged in a specific geometry. The phase and
amplitude of each generator is varied by the electronic driving system to shape the acoustic field.
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Phased arrays allow for real-time beam steering, which means that the acoustic field can be
spatially and temporally designed uniquely for each application. With phased arrays, the ultrasound
focal point can be moved electronically making adjustment and localization of ultrasound energy
more precise and significantly simpler. For large tumor ablation, the focal region can be enlarged
with phased arrays to shorten treatment times (Cain & Umemura 1986;Daum & Hynynen 1999).
For applications where near field structures can distort the focus such as bone in transcranial
therapy or fat layers in abdominal targets, phased arrays can be used to compensate for the
absorbing and refracting media (Clement & Hynynen 2000;Sun & Hynynen 1998). And for tissues
that are moving or are near moving structures, phased arrays can be used to treat the target as it or
its surrounding structures are moving (Seip & Ebbini 1994). The higher field controllability
afforded by phased arrays also allows for sidelobe reduction, minimizing the effects of secondary
foci in the acoustic field (Hutchinson, Buchanan, & Hynynen 1996;Sokka & Hynynen 2000). All
of these features provide a remarkable advantage over single element transducers and opens new
avenues for ultrasound therapy.
1.4 Cavitation
Ultrasound can cause tissue necrosis via two methods: 1) thermal energy absorption and 2)
the implosion of cavitating bubbles induced by higher pressure ultrasound waves. Traditionally, the
thermal mode has been used in FUS treatments as it is better characterized and controlled yielding
lesion sizes and shapes predicted by models (Carstensen et al. 1981;Damianou, Hynynen, & Fan
1995;Hill et al. 1994;Lizzi & Ostromogilsky 1987). FUS thermal ablation is performed with
constant levels of ultrasound intensity well below the cavitation threshold for durations of 1-30
seconds ensuring that the temperature at the focus reaches levels that denature protein causing
tissue necrosis. In addition, therapy in the thermal regime can be carefully monitored with
thermometry techniques as described earlier. However, studies show that there might be utility in
combing acoustic/mechanical effects with thermal effects. In one approach, nonlinear propagation
generated by higher intensity ultrasound has been shown to enhance thermal effects as higher
frequencies generated in non- linear propagation have higher absorption rates (Carstensen, Becroft,
Law, & Barber 1981;Hynynen 1991a;Swindell 1985). But, cavitation with heating shows even
greater promise as cavitating microbubbles not only generate higher harmonics but themselves
significantly enhance absorption and heating.
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Acoustic cavitation, defined as any observable activity involving a gas bubble(s) stimulated
into motion by an exposure to an acoustic field, has also been extensively studied. There are two
basic types of cavitation: stable and inertial cavitation (Duck 1998). Stable cavitation, the less
violent event, refers to radial oscillations of gas bubbles without collapse; these radial oscillations
maybe nonlinear (Leighton 1994). In inertial or transient cavitation, bubbles can grow to twice
their initial bubble size and then have sufficient energy for violent collapse. A series of bioeffects
can occur as a result of this type of cavitation in vivo: shock waves may be propagated; acoustic
energy is often converted to heat yielding high microscopic temperatures (1000-20,000 °K (Apfel
1982;Flynn 1982)); high fluid velocities can be generated; and free radicals might be formed
(Edmonds & Sancier 1983). Inertial cavitation is a threshold phenomenon: in a specific medium,
ultrasound exposures above a specific intensity give rise to cavitation. Cavitation thresholds in vivo
have been studied yielding variable intensity values in different tissue and different frequencies
(Hynynen 1991b;Lele 1977;Prat et al. 1994a;Sanghvi 1998).
1. 4.1 Theoretical Cavitation Models
The physical principles that govern the dynamics of gas bubbles in the presence of an
acoustic pressure field are extremely complex. Several factors are involved in bubble inception,
growth, and collapse. In order to form a cavity in a liquid, sufficient tension is required to pull
apart the liquid (Leighton 1994). In terms of liquid in an acoustic pressure field, negative pressures,
pressures below the ambient pressure, can put the liquid in tension. Impurities in the liquid, the
presence of dissolved gas, preexisting cavities, or crevices in the surfaces of the liquid container
can essentially seed bubbles and all act to lower the tension required for bubble formation and
cavitation. Once bubbles are seeded, they may dissolve, grow, collapse or oscillate in a pressure
field. Bubbles in the absence of an acoustic field generally tend to dissolve due to surface tension,
especially smaller bubbles as surface tension varies inversely with the radius of the bubble.
However, stabilizing agents, such as ions, organic molecules, and surfactants, can sufficiently
lower surface tension to stabilize gas bubbles in vivo. The presence of an acoustic pressure field
dramatically alters the behavior of these bubbles. The simplest way of modeling a bubble's
behavior to an acoustic pressure field is as a driven harmonic oscillator with the gas providing the
stiffness and the surrounding liquid supplying the inertia. First-order viscous damping can be
included by adding a damping term, but the harmonic oscillator neglects surface tension and
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viscous and thermal dissipation and assumes small amplitude oscillations. The harmonic oscillator
model does provide some utility as it adequately describes stable cavitation and provides the means
to calculate resonance frequency for a given bubble radius. This frequency is known as the
Minnaert resonance frequency. For air bubbles in water at 1 atmosphere, the resonance frequency
3 mos- '
simplifies to ~ , where Ro is the equilibrium or initial bubble radius.
Although the harmonic oscillator model predicts bubble behavior under very specific linear
situations, the bubble is essentially a nonlinear oscillator. Several researchers have modeled
nonlinear bubble dynamics over the past half-century. Most models have as their basis the
classical Rayleigh-Plesset equation which models a single bubble in an infinite incompressible
medium and assumes that the bubble motion is spherically symmetric. The equation is shown
below with R as the time-varying bubble radius, p as the density, a as the surface tension, rl as the
shear viscosity, K as the polytropic index, Ro as the initial bubble radius, pv as the vapor pressure,
po as the ambient pressure, and P(t) as the time-varying pressure field at the bubble.
= Po + - Pv + Pv 2a 4R Po - P(t)2 ={(p Ro PV1J R 2 v 2o4R ° t} (1-1)
The Rayleigh-Plesset equation has some serious limitations, a primary one being liquid
incompressibility; this assumption limits the model's ability to completely describe violent bubble
collapse. Many researchers have added compressibility to this model by various mechanisms
(Flynn 1964;Flynn 1975a;Gilmore 1952;Keller & Miksis 1980;Kirkwood & Bethe
1942;Prosperetti, Crum, & Commander 1988), and their results have been validated by experiment
(Gaitan et al. 1992). These equations, despite not being very representative of bubble activity in
tissue, can be used to make predictions of cavitation inception and cavitation thresholds in vivo.
Bubble activity in tissues involves bubble clouds and various bubble stabilizing agents. These
models neglect inter-bubble forces known as Bjerkenes forces that tend to attract bubbles to each
other and are relevant in bubble clouds. Ionic and molecular agents that lower surface tension are
also neglected. In addition, the models assume that the liquid is a Newtonian fluid, whereas tissue
is generally non-Newtonian. These models are also very dependent on initial bubble radii and gas
concentrations, and these parameters are not easily measurable in any local tissue environment.
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Despite the above limitations, these bubble models can provide general trends on cavitation
thresholds and bubble responses to various acoustic pressures. Apfel has used one of these
nonlinear models to predict cavitation thresholds in vivo, and has theoretically shown the
dependence of inertial cavitation threshold on frequency, initial bubble radii, and local gas
concentration (Apfel 1981). In later work, he and his colleagues showed theoretically that transient
bubble collapse occurs when the compressed gas temperature exceeds 5000 K (Holland & Apfel
1989). At this temperature, bubbles are to have acquired sufficient energy for violent collapse. The
gas temperature versus time can be computed from the time-varying bubble radius with some
assumptions on the nature of the gas, and therefore the pressures required for cavitation can be
predicted. Alternatively, Noltingk and Neppiras proposed that transient or inertial cavitation
threshold is reached when - 2 for biomedical frequencies of ultrasound, and Flynn later
confirmed this experimentally. He showed that bubbles that expanded to roughly twice the initial
bubble radius had temperatures similar to Holland and Apfel's predictions and had sufficient
energy to overcome dissipation effects for violent collapse (Flynn 1975b).
The discussed bubble models all ignore another important factor that can contribute to
bubble growth in tissue. Termed rectified diffusion, Harvey et al. observed that in animals, bubbles
in oscillation exhibit a steady increase in Ro during a sustained insonation. The inward diffusion of
gas seems to arise from the fall of internal bubble pressure during the bubble expansion phase
setting up a pressure gradient. Two specific mechanisms are thought to increase the rectified
diffusion capacity, the area effect and the shell effect (Leighton 1994). In the area effect, the
increased bubble size during the expansion phase is thought to provide more surface area for gas
diffusion. With shell effect, the liquid shell around the gas bubble is believed to get thinner during
expansion increasing the diffusion gradient across the bubble wall. These effects have been
theoretically modeled (Church 1988;Crum 1980;Eller 1969;Lewin & Bjomo 1981). Church has the
most sophisticated model, in which, he computes the time varying bubble radius using the Gilmore
equation and then uses this radius to predict the rectified diffusion rate. He then determines the
minimum pressure required to induce bubble growth by rectified diffusion, the rectified diffusion
threshold. Once the threshold is reached, the bubble grows larger during every negative pressure
cycle ultimately reaching a size when violent collapse can occur. Although he concludes that
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rectified diffusion does not occur at ultrasound imaging frequencies and pressures, pressure
waveforms may be designed to reduce the rectified diffusion threshold to induce rectified diffusion
and subsequent cavitation.
Although we cannot fully predict cavitation and its effects in vivo, our current understanding
of bubble dynamics can be used to predict general trends in cavitation and its thresholds in vivo.
These models could serve as valuable tools for designing the optimal cavitation therapy.
1.4.2 Cavitation in Therapeutic Ultrasound
Acoustic cavitation and its role in focused ultrasound therapy has been the subject of much
study and debate during the past half-century. The prospect of in vivo acoustic cavitation was first
described in frogs in 1950 by Fry et. al.(Fry, Wulff, Tucker, & Fry 1950). Their work was soon
followed by Lehmann (Lehmann & Herrich 1953) who should that in vivo cavitation was
potentially the cause of observable blood vessel damage at 1 MHz at some unknown high intensity.
Later studies that investigated the use of focused ultrasound for central nervous tissue destruction
attempted to characterize the parameters need for cavitation and some suggested that cavitation
could be the primary cause of tissue damage (Fry et al. 1970;Lele 1977). Many of these early
studies assessed cavitation damage by examining morphological changes after ultrasound
exposure. These works also showed that when inertial cavitation is induced in vivo, mechanical
tissue destruction close to blood vessels can result, and the generated bubbles can act as ultrasound
scatterers that block wave propagation and subsequent power deposition (Fry, Kossoff, Eggleton,
& Dunn 1970;Lele 1977). In parallel with this earlier investigation, studies in simpler fluids
revealed that acoustic cavitation was accompanied by significant local temperature elevation and
detectable emission of subharmonic or wide band acoustic noise (Coakley 1971;Eller & Flynn
1969). Lele went on to show that transient cavitation in vivo as determined by post exposure
morphological changes produced both subharmonic and ultraharmonic wide band noise emission
thus developing a potentially simple in vivo cavitation detection technique (Lele 1987).
Although focused ultrasound therapy can induce cavitation to mechanically destroy tissue,
the dominant opinion in the ultrasound therapy community has been to avoid cavitation and induce
more predictable and controllable thermal damage with focused ultrasound. However, much has
been learned about cavitation since the early in vivo cavitation studies. The generated gas bubbles
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from cavitation have some potentially useful properties. Besides generating extremely high
temperatures and concentrating acoustic energy at the cavitation site, theoretical models,
extracorporeal, ex vivo, in vitro, and phantom experimental work have shown that gas bubbles in a
focused ultrasound field yield higher ultrasound absorption and therefore higher bulk temperatures
in a zone near the focus (Clarke & ter Haar 1997;Holt & Roy 2001;Hynynen 1991b;Lele 1987).
Higher temperatures yield higher thermal doses at the focus, so this gas bubble enhanced heating
method could lead to more efficient FUS treatment protocols.
The potential benefits of gas bubbles and the presence of occasional cavitation during
conventional thermal mode therapy have led to a growing body of research studying the potential
synergy of cavitation with thermal mode focused ultrasound therapy. Studies have shown that
occasional cavitation and/or boiling during these thermal mode exposures can enhance the heating
effect (Bush et al. 1993;Chapelon et al. 1992) (Sanghvi et al. 1995). When cavitation is detected,
atypical lesion sizes and shapes result. Thermal models with simple assumptions on bubble
distribution and their progression during a sonication have been developed to explain a subset of
these atypical lesions (Chavrier et al. 2000). Bubble kinetics models explaining the enhanced
heating effect from a bubble size perspective have also been developed (Holt & Roy 2001). These
results show the promise as well as the unpredictability of cavitation-enhanced heating. In all of
these studies, the induction and timing of cavitation was unpredictable, and thus the overall
enhanced heating effect was neither predictable nor controllable.
1.5 Ultrasound Phased Array Systems
1.5.1 Array Geometries
Phased arrays were first used in diagnostic transducers in the late 1960s and early 1970s for
improved beam steering (Somer 1968;Thurstone & von Ramm 1974). Therapeutic phased arrays
were not developed until the early 1980s when Do-Huu and Hartemann used phased arrays for
localizing hyperthermia treatments (Do-Huu & Hartemann 1981). Their phased array applicator
demonstrated that transducers diced into concentric rings could scan the focus along the axis of the
transducer. Since then various investigators have developed arrays with different geometries for
both focused ultrasound surgery and hyperthermia. The original single element spherically curved
transducer has been sliced and diced into different geometries (Cain & Umemura 1986;Ebbini &
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Cain 1991a;Fjield et al. 1997). Cain and Umemura proposed the "sector-vortex" geometry by
dividing an array into radial sectors (pie-slices) (Cain & Umemura 1986). The sector-vortex array
consists of a transducer divided into N sectors of equal size as illustrated in Figure 1-1. By
appropriately phasing the sectors, the width of the focus can be controlled. The phase distribution
{i over the N sectors is given by i = mO, for i = 1,2,..., N where m is the vortex mode number
and 9, = 27ri / N, and as m is increased the focal zone is widened Researchers then combined the
sector-vortex array and the concentric ring design (Figure 1-2) to yield an array geometry that can
position the focus along the axis and control the width of the focus (Fjield, Sorrentino, Cline, &
Hynynen 1997;Umemura & Cain 1989). These array geometries can not focus off axis without
considerable secondary foci so linear, tapered, and other types of planar arrays (Benkeser, Frizzell,
Ocheltree, & Cain 1987;Frizzell, Benkeser, Ocheltree, & Cain 1985;Hand et al. 1993;Hutchinson,
Buchanan, & Hynynen 1996;Ocheltree & Frizzell 1987), in addition to spherically curved
transducers diced into a 2D grids (Daum & Hynynen 1999;Fan & Hynynen 1996) were proposed.
These arrays employ several techniques to minimize so-called grating lobes, which are secondary
foci formed as a result of spatial aliasing. These secondary foci cannot be completely eliminated
unless center-to-center element spacing is less than /2 and spatial aliasing is eliminated. The
rationale for this spacing cutoff comes from Nyquist theory as the far field pattern of a periodic
array is governed by sampling theory. Thus, complete control of the acoustic field can only be
achieved with phased arrays with /2 spacing (0.75 mm at 1 MHz) essentially mandating very
large-scale (hundreds to thousands of elements) phased arrays.
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Figure 1-1. Diagram of Sector-Vortex Array adapted from Cain and Umemura.
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Figure 1-2. Diagram of the combined concentric ring and sector-vortex array.
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1.5.2 Phased Array Construction
One major challenge associated with ultrasonic phased arrays is the difficulty in array
construction; however, advances in array fabrication have made construction of these arrays more
routine. Phased arrays are typically constructed from a single piece of PZT (Lead-Zirconate
Titanate), a piezoceramic material. These single pieces are diced into smaller elements and the
spaces are filled with a non-acoustically active dielectric material. Tools for transducer dicing,
critical for planar phased array construction, are the same tools used for wafer dicing in the
semiconductor industry as precision cutting of brittle but hard material is needed. Both diagnostic
and therapeutic ultrasound have also benefited from the advances in the electronic interconnect
industry. Kapton flexible interconnects are now used routinely to connect diagnostic transducers to
the driving and receiving hardware. Advancements in adhesive technologies have also influenced
the rise of phased arrays. Improved epoxies, silicones, and polymers have helped preserve the
structural integrity and water seal of the phased arrays' diced elements while reducing inter-
element coupling. Despite the advances in precision cutting and adhesives, large-scale PZT arrays
with X/2-sized elements for therapy are not feasible. Even if the elements could be appropriately
diced, PZT elements of that size would not be able efficiently transmit high power ultrasound.
1.5.3 Piezocomposites
A solution to many of the problems posed by PZT materials has been provided by a novel
category of piezoelectric materials namely Piezocomposites. In the early 1980's, the Penn State
Materials Research Laboratory of Penn State introduced a new type of piezoelectric material called
1-3 piezocomposites (Gururaja et al. 1980;Gururaja et al. 1984;Gururaja et al. 1985b;Gururaja et
al. 1985c;Gururaja et al. 1985a;Shrout, Bowen, & Schulze 1980). These piezocomposite materials
consist of small piezoelectric rods made typically of PZT embedded in a polymer or epoxy base
(see Figure 1-3). The piezoelectric rods are equally spaced in two dimensionally periodic grid with
varying fill ratios of polymer to active piezoelectric elements. This piezocomposite material
possess significant advantageous over conventional PZT transducers. First, due to the composite
nature (electrically active elements dispersed with non-conducting polymer) of the material, phased
array elements could be created by simply etching the electrode patterns as the polymer matrix
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provides sufficient acoustic isolation between etched elements. Electrode etched piezocomposites
make high-density arrays more practical than costly and labor intensive diced PZT ceramics.
Second, piezocomposites tend to be more polymer than hard PZT crystal rods, and with gentle
heating, the transducer can be molded to deisred shape and size. Shaping of piezocomposites with
heating is not only simpler but allows for more complex geometries than mechanical grinding of
PZT pseudocrystal. Third, the small piezoelement rods embedded in the polymer contain
appropriately narrow dimensioned rods to promote a single longitudinal vibrational mode even
when phased array element width approaches its thickness. With conventional PZT, the forward or
longitudinal transduction efficiency is significantly reduced if the element width-to-thickness ratio
approaches unity as lateral modes are excited with the longitudinal modes (Desilets, Fraser, &
Kino 1978). High-density phased array elements approach unity width-to-thickness ratios;
therefore, high power high density arrays are not really feasible with PZT pseudocrystal. Fourth,
piezocomposites can be designed with multiple resonant frequencies allowing for a greater
bandwidth than PZT or single crystal materials. Fifth, and probably most important to ultrasound
driving system design, the polymer/piezoelement combination has both lower electric and acoustic
impedance than their predecessor materials. Electrically, lower impedance can draw higher
currents for a fixed voltage thereby absorbing more electric power for acoustic energy
transduction. Lower acoustic impedance allows the transducer to be more closely matched to the
liquid coupling medium increasing the transducers ability transmit converted acoustic power into
the medium.
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Figure 1-3. Diagram of a 1-3 composite piezoelectric. The rods represent the PZT and the fill
between the rods (not shown) is typically a polymer.
1.5.4 Ultrasound Driving Systems
Although there is a little published work on the early designs of ultrasound phased array
driving systems, most designs have used a switching amplifier with duty cycle control of power
(Buchanan & Hynynen 1994;Ebbini & Cain 1991a) and the use of counters or delay circuitry to
adjust the phase (Buchanan & Hynynen 1994;Lovejoy et al. 1995). The early systems lacked
feedback circuitry, so amplitude and phasing would drift and precise control of the focus was not
possible without corrections from a hydrophone at the focus. The current state of the art in
therapeutic phased array driving systems utilizes a class D/E switching amplifier core with both
power and phase feedback per channel to provide reliable fields without the need for hydrophone
corrections (Daum 1998). This multi-channel RF amplifier system has a frequency range of 0.5-0.9
MHz, 1-2 MHz or 2-2.5 MHz and is capable of providing up to 60 electrical watts per channel for
up to 256 channels. These systems are adequate for high Q PZT phased arrays with relatively large
elements (much greater than X/2) but are not really scalable for large-scale phased arrays (hundreds
to thousands of elements) due to their high cost and large footprint per channel. In addition,
piezocomposite arrays that are capable of being driven over a wide range of frequencies cannot be
fully utilized with tuned low bandwidth switching amplifiers. Thus, ultrasound driving systems are
currently the limiting factor in therapeutic phased array systems capable of optimal acoustic field
control.
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1.6 Specific Aims
This research investigates cavitation in ultrasound therapy. In the first part of the study, a
new method for synergistically combining cavitation effects with thermal effects to improve
ultrasound ablation is investigated in animal models. Mechanisms of the enhanced effect as well as
monitoring techniques for the therapy are also studied. In the second phase of the research,
techniques for controlling the cavitation field with phased arrays are explored theoretically. These
techniques are to be utilized for not only our proposed cavitation therapy but for all applications
where precise spatial and temporal control of cavitation is necessary. In the final phase of the
thesis, a broadband phased array driving system capable of driving large-scale phased arrays and
implementing the theorized cavitation field control is designed, constructed, and evaluated. This
new design will be a significant advance in therapeutic phased array technology making optimal
field control with precise selection of the ultrasound bioeffect possible.
1. 6.1 Cavitation-Enhanced Ultrasound Heating
In this initial study, we propose an ultrasound protocol that more reliably and predictably
uses gas bubbles to enhance absorption and potentially deliver larger thermal doses in vivo. In
these ultrasound exposures, we hoped to generate gas bubbles at the beginning of the sonication
and then immediately follow with conventional CW heating to utilize the region of enhanced
absorption. If tissue coagulation with this technique is primarily an enhanced thermal effect, MRI
thermometry and dosimetry could potentially be used for monitoring and planning of these
treatments. In order to trigger cavitation, a high intensity burst well above the cavitation threshold
was used, and for the CW ultrasound, conventional thermal mode power levels for typical FUS
ablation times were employed. In addition, visualization and monitoring methods for this heating
method were studied. MRI was used to select treatment locations, monitor temperature during
treatment, and analyze the resulting lesions. Ultrasound monitoring techniques were used to detect
the bubble activity. Previous experimental work has shown that the presence of oscillating and
collapsing bubbles in an irradiated field correlates with detectable acoustic subharmonic emission.
We employed this passive detection technique to monitor the presence or absence of bubble
activity during the burst phase of the sonication. In addition to being useful for monitoring, these
two monitoring techniques provided insight on the mechanism of bubble enhanced heating. If our
exposures generated enough bubbles to increase the ultrasound absorption at the focus, then larger
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coagulated focal volumes without increased nearfield heating are possible. Ultimately, these larger
lesions created with a single ultrasound exposure may greatly improve the rate of tumor
coagulation.
All experiments were performed under MRI (clinical, 1.5T) guidance with one of two eight
sector, spherically curved piezoelectric transducers. The transducer, either a 1.1 or 1.7 MHz array,
were driven by a multi-channel, RF driving system. The transducer was mounted in a MRI-
compatible manual positioning system and the rabbit was situated on top of the system. An
ultrasound detector ring was fixed with the therapy transducer to monitor gas bubble activity
during treatment,. FUS exposures were delivered to 3 tissue types, muscle, fat, and interface, in the
thighs of seven New Zealand white rabbits. The experimental, gas bubble-enhanced heating
exposures consisted of a high amplitude 300 acoustic watt, half second pulse followed by either a 7
W, 14 W, or 21 W continuous wave exposure for 19.5 seconds. Prior to this study, cavitation
thresholds in rabbit thigh tissue were measured at 1.1 and 1.7 MHz, for 100 and 500 millisecond
exposures at 300 acoustic watts, a level significantly higher than the cavitation threshold. The
respective control sonications were 20-second exposures of 14 W, 21 W, and 28 W. During the
exposures, MR thermometry was obtained, and MR T2-enhanced imaging was used to evaluate the
resulting lesions. Specific measures were used to evaluate the differences between the gas-bubble
enhanced exposures and their respective control sonications: temperatures with respect to time and
space, lesion size and shape, and correspondence with thermal dose predictions.
As the initial study showed promise, a second study to optimize the ultrasound parameters
for cavitation enhanced (CE) heating, to understand the specific mechanisms of lesion formation
and shape, to quantify the potential side effects, and to develop methods for monitoring and
controlling this therapy was undertaken. Four different CE heating exposures were tested in vivo in
an effort to find an optimal ultrasound exposure protocol. All of the exposures were initiated with a
high intensity pulse to first induce gas bubbles at the focus. The initial burst was then followed by
constant power continuous wave (CW) ultrasound (similar to the initial study), pulsed ultrasound,
or a combination of CW with pulsed ultrasound. Different power levels for each of these exposures
were also studied. All of these exposures were monitored by MRI thermometry and simultaneous
cavitation detection. Thermometry data in conjunction with cavitation spectrum at different time
points during the sonication were used to access the lesion formation process. MRI T2-weighted
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imaging was used to measure the lesion size, the primary end point in ultrasound therapy.
Additionally, various side effects of these CE heating exposures were also studied. From the
monitoring techniques used in this study, the best metrics for the control of CE heating were
assessed. Finally, the utility of cavitation and CE heating in concentrating energy at the focus and
limiting the ultrasound beams effects in the far field was also assessed. While performing the
ultrasound-enhanced heating exposures, the deposition of ultrasound energy in the farfield was
examined. Such effects could be used to shield vital tissues near the beam from being damaged,
such as bone tissue near treatment locations.
1. 6.2 Theoretical Determination of Optimal Cavitation Field
If cavitation methods are to be established in clinical therapy, precisely focusing the location
of cavitation is absolutely essential. Ectopic cavitation, that is cavitation outside of the target area,
can cause unwanted heating or mechanical damage at locations in the nearfield of the transducer
away from the intended location. This in addition to the high variability of the cavitation threshold
are the major deterrent to cavitation-mediated therapy. In the initial study, high acoustic intensity
were used to induce cavitation. Unfortunately this requires large acoustic powers and appropriate
transducers and amplifiers to supply these powers. In addition, since cavitation thresholds vary
from point to point in tissue, locations near the focal point may exhibit cavitation yielding
undesired lesions. Ideally, if ultrasound powers could be lowered for cavitation inception and if the
cavitation threshold could be preferentially lowered at the transducer focus compared to other areas
in field, ectopic cavitation could be limited. In this study, various multi-frequency sinusoidal
combinations of acoustic pressure waves were tested on a non-linear bubble model to identify
waveform shapes that have lower cavitation thresholds. A bubble model incorporating rectified
diffusion was used to predict the cavitation threshold for a given waveform. The relative predicted
threshold for different waveforms were verified by controlled experiments. Once an optimal
waveform shape that would lower the cavitation threshold at the focus was determined, the
acoustic pressure field generated by spherically curved phased array transducer to yield that
waveform at the focus was computed using the Rayleigh-Sommerfeld integral. The transducer's
field was then analyzed to determine the relative cavitation threshold in the field (named the
cavitation field) in terms of acoustic pressure and intensity. Parameters of the phased array
excitation were varied in order to find cavitation fields in which the cavitation threshold was lower
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at the focus than in the nearfield. These cavitation fields would limit the location of cavitation to
the focus providing precise cavitation site control.
1.6.3 Ultrasound Phased Array System for Improved Acoustic and Cavitation Field Control
To practically implement the multi- frequency phased array therapy to optimally control the
cavitation location, both transducer and ultrasound driving system improvements need to be made.
Till recently, ultrasound phased arrays used in therapy were high Q ceramics and did not respond
well at frequencies away from the resonance. Piezocomposite materials that are both broadband
and are capable of delivering therapeutic intensities are now available and have been developed in
our laboratory. The RF driving system we currently employ for phased array therapy is capable of
providing 60 electrical watts per channel for up to few hundred channels with very precise phase
control, but is limited to providing just one frequency of ultrasound in narrow RF frequency
ranges, 0.5-1 MHz, and 1-2 MHz. In addition the cost per channel is prohibitively high to make
large-scale phased arrays practical.
In this study, a multi-frequency driving system for large-scale ultrasound phased arrays was
developed. The design involves a multi-channel arbitrary waveform amplifier capable of providing
1-2 watts of electrical power per channel in the DC-10 MHz frequency range. This system was
designed for transducers with 50 to 1000+ channels. A 50-channel easily scalable amplifier system
was constructed and tested with piezocomposite transducers. Field patterns suggested for cavitation
control were characterized in water. The proposed system will not only provide the driving
technology for cavitation-enhanced therapy, but should significantly improve other focused
ultrasound therapies.
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2 MRI-Guided Cavitation-Enhanced Ultrasound Heating
2.1 Introduction
In this chapter, we develop an ultrasound protocol that better uses gas bubbles to enhance
absorption and potentially deliver larger thermal doses in vivo. In this ultrasound exposure, we
hoped to generate gas bubbles at the beginning of the sonication and then immediately follow with
conventional CW heating to utilize the region of enhanced absorption. In order to trigger
cavitation, a high intensity burst well above the cavitation threshold is used, and for the CW
ultrasound, conventional thermal mode power levels for typical FUS ablation times were
employed. In addition, visualization and monitoring methods for this heating method are studied.
MRI was used to select treatment locations, monitor temperature during treatment, and analyze the
resulting lesions. Ultrasound monitoring techniques are used to detect the bubble activity. Previous
experimental work has shown that the presence of oscillating and collapsing bubbles in an
irradiated field correlates with detectable acoustic subharmonic emission (Atchley et al.
1988;Hynynen 1991b). We employed this passive detection technique to monitor the presence or
absence of bubble activity during the burst phase of the sonication. If we are successful in
generating enough bubbles to increase the ultrasound absorption at the focus, then this technique
could result in larger coagulated focal volumes without increasing near field heating. Ultimately,
these larger lesions created with a single ultrasound exposure may greatly improve the rate of
tumor coagulation.
2.2 Materials and Methods
2.2. 1 Experimental Apparatus
A schematic representation of the complete experimental setup is shown in Figure 2-1. The
general apparatus included a focused ultrasound therapy transducer, a piezoceramic cavitation
detector ring, and a manual positioner with animal coupling system all in a clinical MR imager.
All measurement and controlling hardware was placed away from the large magnetic field in the
adjacent MRI electronics room.
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Figure 2-1. Schematic of the experimental setup.
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2.2.2 Ultrasound Therapy Transducer
Two separate eight-sector, focused, piezoelectric transducer arrays (10 cm diameter, 8 cm
radius of curvature, manufactured in-house) with resonant frequencies of 1.1 and 1.7 MHz were
used in the experiments. In all experiments, each of the sectors was driven with an identical but
separate radio frequency (RF) signal generated by our in-house multi-channel, computer
controlled, RF driving system (Daum 1998). The multi-channel amplifier/transducer was used
mainly to increase the total power available with each channel capable of up to 60 Watts of
electrical power. All RF signals were in-phase and equal in amplitude thus inducing a single focus
close to the geometric focus. One computer, the therapy workstation, was used to setup the
sonications and communicate with the multi-channel amplifiers. Another computer, the
acquisition workstation, was used to synchronize the sonication, the gas bubble detection, and the
MRI. The transducer array was mounted on a MRI-compatible manual positioning device on the
MRI scanner table.
The acoustic power output and the focal pressure amplitude as a function of applied RF
power were measured with previously reported techniques (Stewart 1982). Acoustic efficiency of
both arrays was determined to be approximately 70%, and acoustic power was calculated from this
measurement and the transmitted RF power (measured by our in-house driving system). The
intensity values were calculated from hydrophone pressure measurements performed in water at
low pressure amplitudes and then extrapolated to higher powers based on the measured acoustic
power. This estimation is true only if the focal spot shape is kept constant (no phase manipulation),
which was the case in these experiments. The water intensity values were adjusted for attenuation
through 10-20 mm of muscle tissue with an average attenuation coefficient of 5 Np/m/MHz.
Using this technique, the calculated intensities at the focus in tissue at 1.1 MHz and 1.7 MHz, were
22.8 W/cm2 per watt of total acoustic power and 35.7 W/cm2 per watt of total acoustic power
respectively.
2.2.3 Sonications
In this study, two types of sonications were utilized. The experimental ultrasound exposure
was designed to induce gas bubbles during the initial phase. These sonications consisted of a 500-
millisecond pulse at 300 acoustic watts followed by 21, 14, or 7 acoustic watts for 19.5 seconds. In
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initial test exposures (data not shown), we found that 500 millisecond 300-watt sonication
regularly induced cavitation in rabbit thigh muscle and fat in vivo at both 1.1 and 1.7 MHz at tissue
depths of 10-20 mm. As a control for each of the 3 cavitation enhanced heating sonications,
standard 20-second continuous wave exposures with the same time-averaged power as the
experimental sonications were performed. Each control sonication, 28 watts, 21 watts, or 14 watts
was positioned adjacent to its respective experimental group sonication so that the resulting lesions
could be compared. Table 2-1 shows all the sonication groups and the corresponding number of
samples in each group.
Table 2-1. Number of Sonications in each control and experimental group
1.1 MHz
Control
14w(20s)
Interface
Muscle
21w(20s)
Interface
Muscle
28w(20s)
Interface
Muscle
Experimental Group
300w(0.5s), 7w(19.5s)
Fat
Interface
Muscle
300w(0.5s), 14w(19.5s)
Fat
Interface
Muscle
300w(0.5s), 21w(19.5s)
Fat
Interface
Muscle
Total
3
2
5
12
4
8
2
13
4
4
3
7
6
6
15
11
19
19
3
4
12
81
1.7 MHz
Control
14w(20s)
Interface
Muscle
21w(20s)
Interface
Muscle
28w(20s)
Interface
Muscle
Experinental Group
300w(0.5s), 7w(19.5s)
Fat
Interface
Muscle
300w(0.5s), 14w(19.5s)
Fat
Interface
Muscle
300w(0.5s), 21w(19.5s)
Fat
Interface
Muscle
Total
8
3
S
15
7
8
11
12
S
6
3
4
5
18
4
7
7
1
5
4
10
74
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2.2.4 Cavitation Detector
In order to detect the bubble activity, a piezoelectric detector ring was constructed from 10
pieces of curved PZT with resonant frequency of 0.6 MHz. The pieces formed a 1 cm thick ring
that was positioned around the transducer array so that all the PZT elements were focused at the
focal plane of the therapy transducer. All of the detector elements were connected in parallel and
wired to the MRI penetration panel via a single coaxial cable. In the MRI electronics room, the
detected signal was buffered and filtered by a LeCroy DA1820A differential amplifier (Chestnut
Ridge, NY) with 10 MO input impedance and a bandpass filter range of 10 kHz - 3 MHz. The
processed signal was then captured over a 100 millisecond window every 4 seconds by a
Yokogawa 7100 storage oscilloscope (Tokyo, Japan) at a sampling rate of 5 MHz. The scope was
triggered to capture the signal at the end of the high power exciter pulse and then during the
subsequent 500-millisecond pauses in MRI temperature imaging. The captured signals were then
transferred to the acquisition workstation and their spectrums were computed. The spectrums at
the different time points during sonication were inspected for subharmonic acoustic emission,
which is characteristic of bubble oscillation (Hynynen 1991b;Lele 1977). Sharp peaks in the
spectrum at the subharmonic were categorized as stable cavitation, and broadband emissions
around the subharmonic were noted as bubble collapse.
2.2.5 Experimental Procedure
Seven New Zealand white rabbits (approximately 4 kg, male) were anesthetized with a
mixture of 40 mg/kg ketamine (Aveco Co., Inc, Fort Dodge, IA) and 10 mg/kg of xylazine (Lloyd
Laboratories, Shenandoah, IA) given as an intramuscular bolus every hour. The animal's body
temperature was constantly monitored with a copper-constantin rectal thermocouple (constructed
in-house). The rabbits were provided housing, food, and veterinary care according to NIH and
Harvard Medical School guidelines. To provide an optimal surface for acoustic coupling, the hair
from the thighs was removed with an electric shaver and hair removing lotion (Nair, Church and
Dwight Co., Princeton, NJ). The animals were placed on their side on a water blanket through
which temperature controlled water was circulated to maintain the body temperature of the animal.
The thigh was coupled to the water bath of the positioning system with a degassed water bag. The
free water surface of the bag coupled the sound into the skin.
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With the animal placed on the positioning system and the focus of the array aligned to the
MRI coordinate system as described below, sonications were performed in different locations in
the each thigh of the seven rabbits. Homogeneous muscle tissue, muscle interfaces at fixed depths,
and fat tissue were each targeted in separate sonications.
2.2.6 MRI
All sonications were performed under MRI guidance and monitoring. Through the course of
the experiments, three basic MR pulse sequences were used: one sequence to locate the array in
relation to the specimen, a temperature sensitive sequence to locate the focus and monitor
temperature during sonication, and a third sequence to identify the coagulated tissue in situ. Prior
to the sonications, fast spin-echo (FSE) Tl-weighted images (TE/TR = 1.6 ms/21ms, FOV = 24 cm
x 24 cm, flip angle = 300, thickness = 10 mm, matrix size = 256 x 128, NEX = 1, bandwidth = 31.3
kHz) were used to position the array with respect to the specimen. Once the array was properly
positioned, temperature images were acquired during a non-destructive low power sonication to
locate the array focus and align the positioning system to the MRI coordinate system. These
temperature images were obtained using the proton chemical shift technique (proton resonant
frequency shift constant = 0.00909 ppm/°C) (Chung, Hynynen, Colucci, Oshio, Cline, & Jolesz
1996). A fast spoiled gradient echo sequence (slice thickness = 3 mm, FOV = 20 cm x 15 cm,
image acquisition time = 4.4 s, TE/TR = 19.7/40.0 ms, NEX = 1, flip angle = 300, matrix size =
256 x 128, NEX = 1, bandwidth = 3.57 kHz) was used to obtain real and imaginary images. From
successive images from this set, the phase difference image, which shows relative temperature
changes, was constructed as shown by Chung et. al. Phase wrap was avoided by subtracting the
images pair-wise and summing along the time direction (McDannold et al. 2000).
Temperature images were also acquired during the sonication and cooling times. For the
20-second sonications in this study, 10 temperature images were obtained over a 40-second period,
6 during the sonication and 4 during the cooling time. A temperature image was acquired every 4
seconds with a 500 millisecond pause between each acquisition. This pause served as a window
for bubble detection without interference from the MRI as described previously. Thermal dose in
the 2D image plane was calculated from the series of images and used to predict lesion size and
shape (Chung, Jolesz, & Hynynen 1999;Sapareto & Dewey 1984). Throughout this paper, the units
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of thermal dose are equivalent minutes at 43 °C. In figures where thermal dose contours are shown:
a 240 minute contour representative of coagulative necrosis (Meshorer et al. 1983) and the 30
minutes contour indicative of some tissue effect (McDannold, King, Jolesz, & Hynynen 2000) are
drawn. After sonication, FSE T2-weighted images (TE/TR = 75/2000ms, echo train length = 8,
FOV = 16 cm, thickness = 3 mm, matrix size = 256x256, NEX = 2, bandwidth = 16kHz) were
used to identify the focused ultrasound lesions and to measure their sizes. All lesions were
measured from T2-weighted images acquired roughly 15-30 minutes after sonication as detailed in
the literature (Chen et al. 1999a;Hynynen et al. 1993). The thermal lesion volume, assumed to be
ellipsoid in shape, was calculated from measurements of the 3 primary axes of the lesion as
observed in two orthogonal image planes. The complete thermal image set was ordered randomly,
and the length of each axis in the image set was measured 3 times. The average axis lengths were
used in the volume computation.
2.3 Results
2.3.1 Temperature versus time at the thermalfocus
Figure 2-2 shows temperature versus time at the thermal focus for different sonications with
the 1.1 MHz transducer. Temperature values shown as solid dots every four seconds represent a 9-
pixel average value around the hottest point in the focus as measured from the MRI temperature
images. The graphs in the left column from the constant power sonications show an exponential
rise in temperature that is typical of conventional continuous wave ultrasound treatments. These
sonications were performed at various depths in the tissue, so variations in the temperature levels
within a particular sonication group can be attributed to differences in tissue attenuation. The
graphs in the right column are temperatures at the thermal focus for the different bubble-enhanced
heating sonications. In these graphs, the solid lines indicate the temperature profiles of sonications
that formed gas bubbles during the initial pulse. Sonications that did not induce bubbles as judged
by the acoustic cavitation detector spectrum are represented with dashed lines. The sonications
where bubbles were induced showed a faster temperature rise within the first 4 seconds than the
sonications without bubble formation. In addition, much higher temperatures were reached in
these sonications. Although the first high power pulse was only 500 milliseconds, the pulse's
temperature effects could be detected over the 4-second image acquisition. These experimental
group graphs showed a greater variability in the temperature values within each sonication group.
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Although, variation in sonication depths was one potential cause of this variability, other bubble
related phenomenon might be involved.
Temperature profiles at focus with 1.1 MHz transducer
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Figure 2-2. Temperature profiles at the focus of the 1.1 MHz sonications. The temperature
curves of interface sonications are indicated in gray, and the muscle sonications are indicated in
black. Dashed lines are used to identify experimental group sonications that did not induce
bubbles during the burst phase.
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Figure 2-3 shows temperature profiles at the thermal focus during the control and
experimental sonications performed with the 1.7 MHz transducer. The graphs in the left column,
the control group sonications, again show the expected exponential temperature rise at the focus
during the continuous wave exposures. Similar to the 1.1 MHz control sonications, the variations
in the temperature trajectories within a sonication group can be attributed to the various depths of
sonication. Deeper sonications had temperature profiles with lower maximum temperatures. The
graphs in the right column are the results of the different sonication powers. In all of pulsed 1.7
MHz sonications, bubbles were observed in the detector signal during the initial high power burst.
This is to be expected at this frequency, as the intensities at the focus were 1.5 times greater than
the intensities at 1.1 MHz for a given value of input RF power. These burst sonication protocols
yielded a rapid temperature rise within the first 4 seconds. In the lowest time-averaged power
sonications (Figure 2-3b), the temperatures in some of the sonications either stayed constant or
decreased slowly after the initial rise. In the two higher time-averaged power sonications,
temperatures after the initial rise increased at higher rates in the highest time-averaged power
sonications (Figure 2-3f) as compared with the temperature profiles of the medium time-averaged
power sonication (Figure 2-3d). When comparing the experimental group sonications with their
respective controls, it is clear that at this frequency, higher temperatures for a longer duration are
observed in the experimental group, and therefore a higher thermal dose is delivered at the thermal
focus with the pulsed protocol.
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Temperature profiles at focus with 1.7 MHz transducer
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Figure 2-3. Temperature profiles at the focus of the 1.7 MHz sonications. The temperature
curves of interface sonications are indicated in gray, and the muscle sonications are indicated in
black.
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2.3.2 Spatial Temperature Maps
Figure 2-4 shows the temperature imaging sequence for a typical bubble-enhanced
sonication. This particular imaging sequence is from a 300 W for 0.5 seconds, 21 W for 19.5
seconds sonication with the 1.1 MHz transducer. The large image shows the temperature map at
20 seconds as viewed from the same plane as the schematic shown in Figure 2-1 with transducer
on the bottom and sonication into the rabbit thigh in the middle of this image. Overlaid on image
are the thermal dose contours indicative of necrosed tissue. The "X" denotes the maximium
temperature voxel within the thermal focus; this point is located at the top of the thermal focus.
The sequence of images below the larger image is a close-up view of the thermal focus and its time
evolution. Inertial cavitation was detected during this sonication, and the MRI temperatures
images show no large anomalies, i.e. noise, image distorting, or artifacts that may be related to
cavitation or the presence of bubbles. This image sequence also shows the spatial progression of
the heating. In the earliest 2 images, a tear-dropped shaped thermal focus can be seen, and in the
later images, the heating expands along the width dimension to round out the thermal focus. The
typical constant power ultrasound sonications do not show this effect and yield an elongated
elliptical thermal focus.
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Figure 2-4. Temperature imaging during an experimental sonication in muscle at 1.1 MHz. The
arrow indicates the rabbit skin interface and the arc at the bottom of the image represents the
transducer. Despite the presence of bubbles, MRI temperature imaging shows no distortion and
can be used to monitor the heating.
The shapes of heating of the previously described sonications were reflected in the tissue
damage seen in the T2-weighted images, such as is shown in Figure 2-5. The two lesions in this
Figure are marked with arrows, and the horizontal line shows the depth of the transducer's
geometric focus. The lesion on the right is the result of the cavitation-enhanced sonication, and the
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lesion on the left is from its respective control sonication. Two key observations can be made from
this typical lesion pair. The experimental sonication yields a more rounded lesion than the control
lesion. Second, the location of the cavitation-enhanced lesion is below the geometric focus of the
transducer, whereas, the control lesions formed around the geometric focus. Similar migration of
the thermal focus and the lesion occurred in all of the sonications where bubbles were induced by
the first pulse.
Figure 2-5. The resulting lesion from the sonication in Figure 2-4. This image shows 2 lesions,
the one on the left is the result of the control sonication and the one of the right is the result from
the experimental sonication. Differences in shape and size can be noted. The control sonication is
elongated, while the bubble-enhanced lesion is more circular and lower than the control lesion.
The sonications discussed above were all done either in muscle or interface tissue. Figure 2-
6 shows the results of a sonication performed with the 1.1 MHz transducer in fat. In this
sonication, the geometric focus of the transducer was positioned in the triangular shaped fat pocket
shown in the T2-weighted image (Figure 2-6c). Figure 2-6a shows the thermal image at the end of
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the 20 seconds of sonication with an overlay of the thermal dose contours. The image shows that
significant heating and tissue damage as predicted by dosimetry occurred below the fat layer, and
that this layer seemingly bounds the lesion from the top. Similar results were observed with all
lesions targeted at fat tissue. The thermal imaging techniques used here are not sensitive to heating
that might occur in fat; therefore, conclusions regarding heating in the fat tissue cannot be made
(Chung, Hynynen, Colucci, Oshio, Cline, & Jolesz 1996). Figure 2-6b is a sequence of images
representing the time course of this sonication. It can be seen in these images that the heating
evolves in the muscle tissue below the fat. In addition, the major axis of the heating seems to be
along the horizontal axis, which is different from the vertical axis heating observed with the
sonications in muscle. Although the heating and the resulting lesion were very close to the skin, no
skin burn was observed in the T2-weighted image or physical exam after the experiment indicating
that the heating spread internally from tissue to internal skin layers as opposed to externally which
is typically caused by poor coupling or cavitation at the external skin surface. This series of
images shows that heating can be monitored in surrounding tissue if fat is sonicated, and that
cavitation enhanced heating might be bounded spatially by interfaces such as skin or fat.
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Figure 2-6. Temperature imaging (A and B) and T2-weighted imaging (C) of a 300W-14W
sonication in fat (indicated by the arrow) and the surrounding tissue at 1.1 MHz. These images
show that heating (A and B) and the resulting lesion (C) were positioned below the fat layer
despite the geometric focus being positioned in the fat. Note that the fat above and the skin below
affect the lesion. No evidence of external skin bum was observed.
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2.3.3 Lesion Size and Shape
It was shown earlier (Figure 2-6) that cavitation enhanced heating produced different shaped
lesions. The Figure 2-7 T2-weighted image shows that lesion shape and lesion position differ
between the control and experimental sonications at the different energy levels. The figure shows
with the arrows from left to right the resulting lesions from 3 bubble-enhanced heating sonications
at successively lower power levels. The line indicates the position of the geometric focus. These
lesions are wider than their neighboring control lesions (located to the right for the 2 higher power
sonications) and situated closer to the transducer below the geometric focus. This image also
shows that higher power cavitation-enhanced sonications translate into larger lesions as can be
seen from the relative sizes of the arrow-marked lesions. Figure 2-8 shows two thermal dose
contours per lesion overlaid on the T2-weighted image. The internal thermal dose contours
represent 240 minutes and the outside contours represent the 30 minutes level. The thermal
dosimetry, specifically the 240 minutes contours predictive of tissue coagulation, coincides with
the lesion size and shape for both the experimental and control group sonications. This agreement
was observed with all the lesions. In the higher power sonications on the left side of the image, a
hyperintensive region can be seen to the left of the thermal contours. This area is most likely
edema as it is outside the hypointensive region indicative of a lesion. This image shows that
thermal dosimetry can be used with cavitation enhanced heating to predict lesion size and shape.
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Figure 2-7. T2-weighted images after 5 consecutive sonications at 1.7 MHz showing the
resulting lesions. From left to right, the arrows indicate the 300W-21W, 300W-14W, and 300W-
7W sonications respectively. The control lesions for the first two bubble-enhanced sonications
are also visible immediately to the right of the respective experimental sonications.
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Figure 2-8. T2-weighted images from the same 5 consecutive sonications with the thermal dose
contours overlaid. The image shows that the dose contours match well with the actual lesions
observed in the T2-weighted images for both the control and experimental sonications.
In addition to making qualitative lesion assessments from T2-weighted imaging, lesions size
and shape were also quantified. Table 2-2 and table 2-3 show two metrics for lesions made with
the 1.7 MHz transducer. Lesions with clear boundaries were formed more easily at the higher
frequency due to the higher intensity at the focus, so the higher frequency lesions were quantified.
In table 2-2, the relative volumes of experimental group lesions to that of its equivalent power
control group lesions are shown. Measurements for lesions in muscle are separated from those
made in the interface. At the lowest power level, the control sonication often yielded no lesion
while the bubble-enhanced sonication produced a lesion, so the mean relative lesion volume is
represented by infinity. At the two higher power levels, the mean lesion volume was in general 3
times larger when the heating was cavitation enhanced. Table 2-3 shows lesion width to height
ratios. This metric served as indicator of lesion shape. Lower ratios indicate more elongated cigar
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shape, and higher ratios that approach 1 indicate a more circular shape. The ratios in this table
show that the gas bubble enhanced sonications in muscle produced less elongated lesions or lesions
that approach a circular shape than their respective control sonications. This is clear when
comparing the metric at the different power levels: 0.55 to 0.75 for the lowest power (control to
experimental sonications), 0.52 to 0.96, and 0.55 to 0.80 for the highest power level. This data
confirms the results seen in Figure 2-5 and Figure 2-7. With interface lesions, no significant
differences in width to height ratio are noted with the 2 lower power levels; however, at the highest
power level, a 0.48 to 0.70 difference is observed. The width to height ratios in fat, 0.76, 1.06, and
1.81, indicate a more circular or wider lesion. This is consistent with the imaging shown in Figure
2-6.
Table 2-2. Ratios of experiment to control lesion size with 1.7 MHz Transducer
Experimental Group Mean Relative Lesion Volume Standard Deviation
300 watts(0.5s), 7 watts(19.5s)
Interface 6.29 2.29
Muscle oo
300 watts(0.5s), 14 watts(19.5s)
Interface 3.22 1.58
Muscle 2.93 0.54
300 watts(0.5s), 21 watts(19.5s)
Interface 3.53 0.76
Muscle 3.25 1.08
Note: Lesion measurements for 1.1 MHz were not included as lesions were not observed in many
of the control sonications and therefore more difficult to quantify.
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Table 2-3. Lesion width to height ratios for all sonication groups at 1.7 MHz
Sonication Group Mean Lesion width/height Standard Deviation
14 watts (20s)
Interface 0.88 0.58
Muscle 0.55 0.21
300 watts(0.5s), 7 watts(19.5s)
fat 0.76 0.21
Interface 0.82 0.19
Muscle 0.75 0.10
21 watts (20s)
Interface 0.71 0.17
Muscle 0.52 0.06
300 watts(0.5s), 14 watts(l9.5s)
fat 1.06 0.28
Interface 0.70 0.17
Muscle 0.96 0.23
28 watts (30s)
Interface 0.48 0.15
Muscle 0.55 0.23
300 watts(0.5s), 21 watts(19.5s)
fat 1.81 0
Interface 0.70 0.14
Muscle 0.80 0.14
2.4 Discussion
The purpose of this study was to investigate gas bubble enhanced heating in vivo and the
potential MRI and ultrasound monitoring techniques for this type of heating. The study
demonstrated that cavitation could be used reliably to create significantly larger lesions (three
times larger lesions than with conventional focused ultrasound) in vivo. MRI thermal techniques
were successfully used to monitor the thermal effects mediated by the bubble-enhanced exposures
as lesions predicted by MRI dosimetry were produced. This strong correlation of MRI dose maps
to the lesions observed in the T2-weighted images confirms that bubbles do not excessively
interfere with the MRI thermometry technique.
The MR imaging and ultrasound cavitation detection used to monitor and assess these
treatments also facilitated the study of the mechanism behind cavitation enhanced heating. In our
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study, we attempted to induce gas bubbles at the onset of the ultrasound exposure with a high
pressure amplitude burst. In almost all of the exposures, inertial cavitation was induced with this
pulse, which was confirmed with the wideband subharmonic emission captured by the detector
ring. Of all the sonications performed in this study only a few of the sonications provided no
evidence of inertial cavitation. These sonications fit in to one of two categories: 1) deep tissue
sonications, which presumably lowered the ultrasound intensity at the focus below the cavitation
threshold; 2) sonications with poor acoustic coupling to the rabbit thigh which was confirmed with
T2-weighted MR imaging after the sonication. In all sonications where inertial cavitation was
induced, a fast temperature rise at the thermal focus was observed in the MRI thermometry.
Furthermore, the fast immediate temperature rise was only seen in exposures with inertial
cavitation. This direct one-to-one correlation establishes the connection of gas bubbles in vivo with
increased absorption and higher temperatures at the focus. The fast temperature rise occurs beyond
the 500-millisecond burst during which inertial cavitation was observed. This result indicates that
the induced gas bubbles may persist (Hynynen 1991b) enhancing the local absorption and the
associated heating. In some treatments, especially the higher power exposures, temperatures
continued to rise at a high rate for the duration of the ultrasound exposure indicating that bubbles
might be present throughout the sonication all the while enhancing the heating effects.
In addition to helping trace the time course of bubble enhanced heating, the MR imaging
also showed the two-dimensional spatial evolution of heating. The MR temperature maps and the
follow-up T2-weighted images clearly showed that the thermal focus and the resulting lesion are
located proximal to the geometric focus. The impedance mismatched gas bubbles induced at the
focus most likely acted as an acoustic barrier, reflecting and scattering the ultrasound beam back in
the direction of the transducer thereby increasing the heat deposition immediately proximal to the
geometric focus. This bubble barrier theory also explains the generally wider thermal foci
observed with cavitation enhanced heating as the reflection prevents heating on the distal side of
the geometric focus. The MR images also provide clues as to how the bubbles propagate spatially.
Some of the sonications, specifically the ones targeted at the fat, showed that heating and the
resulting lesions were affected by the surrounding tissue boundary. These tissue boundaries, the
muscle-fat boundary and the muscle-skin boundary appear to limit and concentrate the heating to
the muscle tissue. The tissue boundaries might be acting as physical barriers for bubble
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propagation once the initial bubbles are induced in the muscle. If this rough MRI observation can
be confirmed with more sensitive ultrasound diagnostic methods, it could potentially be very useful
in limiting tissue coagulation within an organ boundary.
Although our monitoring techniques were helpful in providing an explanation for the
thermally mediated tissue effects, questions remain. First, our data does not indicate whether gas
bubbles were induced in the muscle fiber, interstitial space, or in the blood stream. The specific
location of induction could have implications on bubble evolution and any secondary sites of
cavitation. The high rate of temperature rise for 2-20 seconds at the thermal focus, suggests that
the bubble cloud is stationary, but the monitoring techniques used are not sensitive enough to
detect very small bubble populations outside the focal region. Second, the possibility of
microscopic cavitation events outside the treatment zone and their associated damage cannot be
completely excluded. MRI T2-weighted images are excellent for detecting lesions, swelling events,
and major hemorrhage events, but microvascular events or cellular level effects cannot be
discerned from this imaging method. We can infer that ultrasound intensities are significantly
below the cavitation threshold outside the focal area, but our monitoring methods do not precisely
detect this off focus cavitation activity. In this study, histological analysis was not performed, so
we do not precisely know the mode of tissue necrosis. Although MRI lesions from cavitation
enhanced heating appear similar in T2-weighted images to MRI lesions from conventional heating
and the MRI dosimetry predicts these lesion shapes and size, histology needs to be performed to
confirm that these lesions were indeed thermally induced.
This study shows the feasibility of MRI guided cavitation enhanced heating in vivo;
however, improvements are needed to make this technique more suitable for human therapy. Our
sonication protocol requires very high pressure amplitude bursts to induce bubbles. This
requirement makes deeper sonications more difficult as pressure amplitudes are reduced by tissue
attenuation. To adjust for this, it may be possible to superimpose the second harmonic or the half
sub-harmonic frequency on the high pressure amplitude pulse. This technique, suggested by
Umemura and Kawabata apparently lowers the cavitation threshold, and if the ultrasound field was
designed so that superimposition occurs exclusively at the focus, unwanted cavitation effects
associated with high pressures could be reduced (Umemura & Kawabata 1996a). In our treatment
protocol, gas bubbles were grown at the focus with an initial high intensity burst, and these bubbles
52
were used to enhance the subsequent heating. Cavitation enhanced heating could also be
performed with injected gas bubbles eliminating the need for inertial cavitation and the high
intensity burst. Injected bubbles have been used for cavitation mode therapy, but they can also be
used to reduce the ultrasound power requirements for thermal ablation. Bubbles could be injected
in the blood stream upstream of the targeted tissue, and lower power ultrasound exposures could be
used for heating. This would eliminate two potential pitfalls, the high intensities needed to
generate gas bubble populations and use of inertial cavitation, a less controllable phenomenon than
stable cavitation. This study has shown that MRI and passive ultrasound cavitation detection can
be used to monitor cavitation enhanced heating, so similar techniques could be used to monitor the
injected bubble therapies.
Monitoring techniques could also be improved. In this study, the acoustic emission detected
by the ring transducer was only recorded during the high intensity pulse. This provided a high-
resolution spectrogram of the cavitation activity during the inertial cavitation phase; however,
bubble activity during the latter heating phase was not monitored. If the acoustic emission is
recorded throughout the ultrasound exposure, the bubble activity could be better monitored and
controlled. The cavitation detector in this study was oriented toward receiving emission from the
geometric focus. The detector was sensitive to events in the vicinity of the focus, but no further
spatial information can be obtained with this detector. A cavitation detector array with different
elements oriented at different depths could provide more spatial information regarding the
cavitation events. In addition, conventional diagnostic ultrasound could be used to supplement
passive cavitation detection. These time and spatial resolution improvements in the cavitation
detection will help treatment monitoring but also help us better understand the mechanism.
In conclusion, this study has shown the feasibility of MRI guided bubble enhanced heating in
vivo. It has shown that bubble effects can reliably be used to augment conventional focused
ultrasound therapy by producing larger lesions that can be predicted with MRI thermal dosimetry.
In addition, a passive ultrasound cavitation detection scheme was successfully used in vivo to
monitor the gas bubbles critical to this therapy. The study suggests that lesions can be obtained
with less total energy if cavitation in used to enhance heating. This technique could potentially
solve the power limitation problems faced by intracavitary and similar therapies where space
limitations don't allow for large area, high power, transducers (Hutchinson & Hynynen
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1998;Sokka & Hynynen 2000). Finally, this study shows that bubble enhanced heating can be
monitored by MRI thermometry and ultrasound passive cavitation detection in real time; therefore,
these monitoring techniques could potentially be used in a closed loop control of the ultrasound
treatment yielding shorter treatment times and precise lesions.
54
3 Cavitation-Enhanced Ultrasound Heating: Mechanisms, Acoustic and
MRI Monitoring, and Control Techniques
3.1 Introduction
The previous chapter showed the feasibility and potential benefits of MRI monitored
cavitation-enhanced heating. The objectives of the study described in this chapter were to optimize
the ultrasound parameters for cavitation enhanced (CE) heating, to understand the mechanisms of
lesion formation and lesion shape, to understand the potential side effects, and to develop metrics
that could be used for control. We evaluated four different CE heating exposures in an effort to
find an optimal ultrasound protocol. All of the exposures were initiated with a high intensity pulse
to induce gas bubbles at the focus at the onset of the sonication. The initial burst was then
followed by constant power continuous wave (CW) ultrasound (similar to the previous study),
pulsed ultrasound, or a combination of CW with pulsed ultrasound. Each of these exposures
elicited a different cavitation versus time profile allowing us to test the effects of a variety of
cavitation-time profiles. All of these sonications were monitored by MRI thermometry and
simultaneous passive cavitation detection throughout the exposure and during the cooling phase.
Thermometry data and the cavitation spectrum at different time points were used to access the
lesion formation process. From the two monitoring techniques used in this study, potential metrics
for the control of CE heating, such as MRI spatial temperature evolution and cavitation spectral
content, were investigated. Additionally, MRI T2-weighted imaging was used to measure the
lesion size, the primary end point in ultrasound therapy, and the resulting lesion sizes from the
different exposures were compared. Finally, the primary side effects of these CE heating
exposures, nearfield heating, irregular lesion shape, and skin heating, were also studied.
3.2 Materials and Methods
3.2.1 Experimental Apparatus
The experimental apparatus used in this study was similar to the first study and consisted of a
focused ultrasound therapy transducer, a piezoceramic cavitation detector transducer, and a manual
positioner for the transducers within a water based ultrasound coupling system, all placed in the
bore of a clinical 1.5T MR imager. The rabbits were rested on a platform above the coupling
system as indicated in the Figure 2-1. All control, measurement, and ultrasound driving hardware
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were positioned away from the large magnetic field in an adjacent electronics room. To reduce RF
interference, all connections to the electronics room from the shielded MRI bay were passed
through a penetration panel. All hardware aspects of the setup, the ultrasound therapy transducer,
ultrasound driving system, and cavitation detector, were identical to the first set of experiments.
Ultrasound exposures were performed in different locations in each thigh muscle of the twelve
New Zealand rabbits prepared as discussed in the previous chapter.
3.2.2 Cavitation Enhanced Heating Sonications
Cavitation enhanced (CE) heating was investigated in rabbit thigh muscle. Five basic types
of sonications were utilized: 4 experimental sonication types involving cavitation and one type
acting as the non-cavitating control. The experimental ultrasound exposures were designed to
induce gas bubbles at the onset of ultrasound, thus all of these 20-second sonications were initiated
with a 500-millisecond pulse at 300 acoustic watts. This power level was confirmed in the earlier
study to be above the cavitation threshold in muscle. Figure 3-1 shows the timing diagrams of all
the sonication types. For each sonication type, 3-4 different sets of power levels were studied. The
type I sonication, which was the subject of the previous study consisted of a 500-millisecond pulse
at 300 acoustic watts followed by 7, 14, or 21 acoustic watts for 19.5 seconds yielding ultrasound
exposures with a total energy of 290 J, 420 J, or 560 J respectively. The type II sonication was
initiated with the same 300-watt acoustic pulse, but followed by 100-millisecond pulses of 70, 140,
or 210 acoustic watts every second. These sonications have equivalent total energies of 290, 420,
or 560 Joules. In the type III exposure, the acoustic energy was divided into 50-millisecond pulses
of 70, 105, or 140 acoustic watts every half second following the initial 300-watt burst yielding
total energies of 290, 350, and 420 Joules respectively. The highest energy level was attempted
but significant side effects, which will be discussed later, made further study unwarranted. In the
type IV sonication, the 500-millisecond cavitating pulse was followed by 7 watts of constant
ultrasound with a 50-millisecond, 140-watt burst every second (total energy of 420 J). All of these
sonications were performed in in vivo rabbit thigh muscle at 1.7 MHz at tissue depths of 10-20
mm. As a control for each of the 4 energy levels, standard 20-second constant power exposures of
14.5, 17.5, 21, 28 watts were performed. Each control sonication was positioned adjacent to its
respective experimental group sonication so that the resulting lesions could be compared. Table 3-
1 shows all the sonication groups and the corresponding number of samples in each group.
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Figure 3-1. Time profile of the 4 cavitation-enhanced heating exposures.
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Table 3-1. Number of Cavitation Enhanced Heating Sonications
Sonication Type Total Energy Number of
Sonications
Type I 43
300 W (0.5 s), 7 W (19.5 s)* 290 J 15
300 W (0.5 s), 14 W (19.5 s)* 420 J 17
300 W (0.5 s), 21 W (19.5 s)* 560 J 11
Type II 41
300 W (0.5 s), 70 W (0.1 s every 1 s) 290 J 18
300 W (0.5 s), 140 W (0.1 s every 1 s) 420 J 15
300 W (0.5 s), 210 W (0.1 s every 1 s) 560 J 8
Type III 38
300 W (0.5 s), 70 W (0.05 s every 0.5 s) 290 J 16
300 W (0.5 s), 105 W (0.05 s every 0.5 s) 350 J 8
300 W (0.5 s), 140 W (0.05 s every 0.5 s) 420 J 14
Type IV 8
300 W (0.5 s), 7 W, 140 W(0.05 s every 1 s) 420 J 8
Control 650
14.5 W (20 s)* 290 J 29
17.5 W (20 s) 350 J 9
21 W (20 s)* 420 J 27
28 W (20 s)* 560 J 12
Total 780
*Includes data in muscle tissue at 1.7 MHz from the earlier study
3.2.3 Cavitation Detector Signal Acquisition and Analysis
In the cavitation enhanced (CE) heating exposures, the amplified and filtered detector signal
was digitally captured at different time points during and after the sonication. In all of these
exposures, the timing of the sonication, MRI imaging, and detector signal acquisition were
controlled by the control/acquisition workstation. Prior to sonication, the RF driving system was
programmed with the different power levels for a given exposure and setup for external triggering.
Similarly, the MRI thermal imaging pulse sequences were selected and prepared for external
triggering. Precise timing of the ultrasound exposure and the monitoring hardware was provided
by the Wavetek 395 100-MHz Arbitrary Waveform Generator (Fluke Corp., Everett, WA). The
Waveform generator was programmed with the timing of the appropriate sonication type and was
triggered by the control/acquisition workstation via the parallel port to start the sonication. The
output of the generator was connected to the RF driving system to trigger the ultrasound, to the
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MRI to trigger the thermal imaging, and to the oscilloscope to trigger the detector signal
acquisition. The scope was configured to acquire at 10 Megasamples/second during the last 10
milliseconds of each ultrasound pulse with a minimum of at least one acquisition every 0.5 second.
Thus for all sonications, the detector signal was acquired at half second intervals timed to coincide
with the therapy pulses. In the first 4 rabbits, the detector signal was only acquired every four
seconds during a 500-millisecond MR imaging pause to minimize MRI interference, but the need
to monitor bubble activity more often and the minimal interference from the MRI motivated the
0.5 second acquisition interval.
For every sonication (besides the first 4 rabbits), 59 time points of the detector signal
covering 29.5 seconds were acquired. The data was transferred after the sonication from the
oscilloscope to the acquisition/control computer via the IEEE 488.2 bus for later analysis in
MATLAB. In MATLAB, the detector signal at each time point was digitally filtered with a
bandpass range of 0.4 to 4.8 MHz, and the spectrum at each time point was calculated using the
Fast Fourier Transform (FFT). The energy-density spectrum was obtained by squaring the
magnitude of the FFT. Specific energy bands and local maxima of the spectrum were investigated
as potential metrics for CE heating monitoring and control. First, the 3 peak values and their
corresponding frequencies were identified and analyzed. Second, the spectrum was integrated over
different frequency ranges, 0-1 MHz, 1-1.6 MHz, 1.75-2.2 MHz and 3.45-5 MHz, as the energy
levels in these different bands have been correlated with different phenomena. As an example,
Figure 3-2 shows three spectra from different time points of an exposure. In Figure 3-2a, the
spectrum during the initial cavitation pulse is shown with the characteristic large energy in the 0-1
MHz band; in (b), the spectrum during a non-cavitating pulse is shown without any broadband
content; and in (c), the spectrum of MRI interference is shown. Thus, the energies in the 0 to 1
MHz band were used to quantify the amount of inertial cavitation at each time point. As seen in
Figure 3-2c, high spectral content in the 1 to 1.6 MHz band was unique to MRI interference, so
when the detector signal exhibited large energies in this range, those time points were left out of
the cavitation spectral analysis. Roughly 7-10 non-consecutive time points per exposure always
after the 13-second mark were eliminated for excessive MRI interference.
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Figure 3-2. (a) Spectrum of the sample cavitation detector signal during an inertial cavitation
event. (b) Spectrum of the detector signal during a low intensity continuous wave exposure, and
(c) spectrum of the detector signal with no ultrasound during a MR imaging sequence.
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3.2.4 MRI
All sonications were done under MRI guidance and monitoring. Through the course of the
experiments, three basic MR pulse sequences were used: one sequence to locate the array in
relation to the specimen, another temperature sensitive sequence to locate the focus and monitor
temperature during sonication, and a third sequence to identify the coagulated tissue in situ after
the exposures. The details of the MRI sequences are described in the previous chapter.
All lesion volumes were measured from the post exposure T2-weighted images. The thermal
lesion volume, when ellipsoid in shape, was calculated from measurements of the 3 primary axes
of the lesion as observed in two orthogonal image planes with assistance from the overlaid dose
contours on the lesions. The complete thermal image set was ordered randomly, and the length of
each axis in the image set was measured 3 times. The average axis lengths were used in the volume
computation. If lesion shapes were irregular, the overall shape was reduced to combinations of
simpler shapes, ellipsoids, cylinders, and/or cones, and the volumes were calculated after
measuring the appropriate lengths in the two orthogonal image planes.
3.3 Results
3.3.1 Cavitation Spectra versus time
The cavitation-time profile for the different exposure types was used to assess the different
mechanisms involved in CE heating. Figure 3-3a shows the cavitation spectral energy in the 0.4
MHz to 1.0 MHz band versus time for the different sonication types, and Figure 3-3b shows a
zoom in of the same data with errorbars for the first ten seconds of sonication. All the exposures
presented in this figure were performed at an equal ultrasound energy level of 420 Joules. For
this figure, the energy versus time curve for each sonication was first subtracted by the baseline
energy when no ultrasound was on and then normalized to the maximum energy for that
sonication. These adjustments yield a curve showing relative energies versus time. The curves for
different sonication types were then grouped, and the mean and standard deviation were calculated
and plotted in the figure shown. It should be noted that in all the data shown, inertial cavitation
was observed with the spectrum analyzer during the initial high power cavitation pulse. Control
data is not shown in this figure, as the spectral energy remained relatively constant. Ultrasound
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exposures that produced irregular or split lesion shapes (defined in a later section) were removed
from this analysis.
- CE: 20W CW (I)
. CE: 200W,100ms,ls (11)
*. CE: 200W,50ms,0.5s (111)
. CE: 100W, 50Oms, s, 10WCW(IV)
10 15
(a)
--v CE: 20W CW (I)
.. A CE: 200W,100ms,1s (11)
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A CE: 100W, 50ms, ls, IOWCW(IV)
(b)
Figure 3-3. Spectral energies of the detector signal in the 0 to 1 MHz band versus time for the
cavitation enhanced heating sonications. (b) shows a close of (a) with errorbars.
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This subharmonic frequency band, as noted earlier, is used to gauge the presence and level of
inertial cavitation. The data suggests that in all sonications except type IV, inertial cavitation
persists no longer than about 7 seconds. However, there is large variability within each group
during the first 1.5 seconds. The type IV sonication on occasion exhibited higher levels of spectral
energy at time points after the initial burst. It can also be inferred from the high cavitation energy
levels at later time points that the type IV sonication induced inertial cavitation at later times
coinciding with the high intensity pulses. The type II and III sonications, which included higher
intensity pulses without the CW ultrasound in between, did not induce inertial cavitation at later
time points. As mentioned above, the data for the few exposures producing split lesions were
removed. Their spectral energy time profiles were highly irregular. These split lesions, sometimes
though not always, yielded spectral energy time profiles which showed multiple inertial cavitation
events later in the sonication. These irregular cavitation profiles were only observed in the case of
split lesions, and could potentially be used as an indicator of irregular CE heating.
The time profile of the cavitation spectral energy in the 1.75 to 2.2 MHz energy band and the
half-harmonic peak value were also studied in a similar fashion. From the spectral energy versus
time curves, the length of time in which the spectral energy was above the base line value was
calculated for each exposure and plotted in the bar graph shown in Figure 3-4. Figure 3-4a shows
the time duration data from the 0.4 to 1.0 MHz energy band which is taken from Figure 3-3; (b)
shows the time duration of the half-harmonic peak, and (c), the 1.75 to 2.2 MHz frequency band.
Figure 3-4a confirms the results from the earlier figure and shows the relatively short persistence of
inertial cavitation in the first 3 sonication types. The half-harmonic peak seen in Figure 3-4b is a
general indicator of stable cavitation (discussed earlier). For all sonication types, stable cavitation
persists longer than inertial cavitation, and this trend is especially pronounced for the first 3
sonication types. The data suggests that although the bubble seeding inertial cavitation process
terminates earlier, bubbles persist at the focus, undergo stable cavitation, and contribute to the
enhanced heating. The ultraharmonic energy band, whose time duration is shown in (c), is
influenced by inertial cavitation, but does not exclusively indicate this form of cavitation. This
energy band also captures the effect of non-linear propagation and the resulting non-linear heating
that occurs with high intensity acoustic fields. The bar graph, (c), presented is very consistent with
high intensity induced ultraharmonic non-linear effects. The time-duration of the ultraharmonic
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band for the type I sonication is limited to the first high intensity pulse, while the ultraharmonic
energy for the other exposure types, which are high intensity throughout the exposure, persist for
the whole sonication time. Finally, Figure 3-4d shows the average energy in the ultraharmonic
band after the first pulse for all exposures. The type II sonications, which include the highest
intensity pulses for the longest duration, show the highest average spectral energy. Ultraharmonic
ultrasound energy has a higher absorption in tissue than the fundamental and therefore higher
temperatures and thermal doses might be present in the type II if non-linear heating is a major
factor. By comparing the temperature and lesion size data of the type II sonication to type III
sonications that are similar in most respects except the ultraharmonic energy level, the effects of
ultraharmonic heating will be assessed later. With the 4 exposures, we have one exposure with
limited inertial and stable cavitation (I), one exposure which has significantly more non-linear
energy (II), one exposure which has a longer persistence of stable gas bubbles without high levels
of non-linear energy (III), and one exposure which exhibits moments of inertial cavitation
throughout the exposure (IV).
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Figure 3-4. Time duration of spectral energy in the (a) subharmonic energy band, (b) half-
harmonic peak, and (c) the ultraharmonic energy band. (d) shows the relative average energy in
the ultraharmonic band for all exposure types.
3.3.2 Temperature versus time at the thermal focus
Figure 3-5 shows temperature versus time at the center of the thermal focus for the different
sonication types. In (a)-(e), each gray line represents the 9-pixel average temperature value around
the hottest point for each exposure within that sonication type. The average temperature of all
sonications within a group is shown with a symbol and connected by a black line. For each
temperature average, the standard deviation errorbars are also shown. Variations in the
temperature levels within a particular sonication group can be attributed to differences in local
tissue attenuation and absorption as these sonications were performed over a range of tissue depths
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in various areas of different rabbits. All the bubble-enhanced heating sonications showed a faster
temperature rise within the first 4 seconds than their respective control exposures; Figure 3-5f
clearly shows this trend. In addition, the figure also shows that the bubble-enhanced heating
exposures produce much higher temperatures than the control for the first 10 seconds delivering a
larger thermal dose. Another trend of note is the actual shape of the temperature versus time
profile for the different exposures. The control sonications yield the typical exponential
temperature rise. The types II, III, and IV sonications produced a step response type temperature
rise, and the type I exposures generate a step temperature rise followed by a slow exponential
increase. Although the first high power pulse was only 500 milliseconds, all the CE heating
exposures yield sustained temperature rises for many seconds eliminating high ultrasound power as
the sole explanation for the these heating profiles. The bubbles, not the high intensity pulse alone,
enhance the heating.
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Figure 3-5. MRI Temperature versus time curves at the thermal focus for all the exposure types.
The gray lines represent the temperature curves of distinct exposures, while the dark lines is the
average of all these exposures.
67
4
3
2
1
j
0 -ool
o 4-CE: 200 W,lIOfms,lIs (II)0
CD 4(
0 30
g 2
CD
4u
3
2
-- CE: 200W,50ms,0.5s (III)
oX~~~~~~~ 
0
0
4()s
U
0
0
0
E: W, 50ms, Is, W CW (
- Control: 30W CW
-V- CE: 20W CW (I)
-+- CE: 200W,lOO1ms,ls (II)
-U- CE: 200W,50ms,0.5s (III)
-- CE: 100W, 50ms, Is, 10W CW (IV)
.
.^
I
1
)s
3.3.3 Spatial Heating Distribution
Figure 3-6 shows MRI temperature images at consecutive time points during 5 different
sonications representing the different spatial temperature profiles seen in this study. All images are
taken in a plane perpendicular to the transducer face along the diameter with the transducer located
below the image plane. At the end of each row of images, the resulting lesion with thermal dose
contours is shown on the MRI T2-weighted image. In those images, the hottest spot is marked with
an "X", and the 9-pixel region used for the temperature curves noted earlier is highlighted by a
white square. The first row (a) depicts the spatial temperatures during a 21-watt control sonication.
The thermometry shows the development of the typical cigar-shaped lesion from conventional
ultrasound heating and similar temperature evolutions were seen in all the control lesions. The
second row (b) shows the temperature images for a type I, 420-joule exposure. The development
of the round shape reported in the earlier study, can be seen in these images. The images, in
general, show a single hot spot and this hot spot grows with increasing time. The dark spot located
in the center of the thermal focus is consistent with boiling and is indicative of the high
temperatures with this exposure. This type of spatial heating progression can be seen in all CE
heating exposures, but occurs more often with the type I exposure. The third row (c) shows the
sonication progression from another type I, 420-joule exposure. In this exposure, multi-spot
heating can be seen during the first time points which eventually blend and create a single more
oval shaped sonication. This is another CE heating profile, but is more common in the type II and
III exposures than the others. In the fourth row of images (d), we see the temperature progression
leading to a "teardrop" or "tadpole" shaped lesion. For this lesion shape, heating occurs both
below the focal point similar to (b) and at the transducer focal point eventually blending to create
the tear drop shape. This heating progression is seen more often in the type I and IV exposures.
The last row shows (e) the progression of a split-shape lesion. In this heating exposure, the
temperatures begin as they do in (d), but the heating at the two locations evolves without out
significant blending yielding a split lesion as seen in the T2-weighted image. These lesions
occurred almost exclusively with the type II and type III lesions. Many, but not all, of these lesions
showed inertial cavitation activity beyond the first 5 seconds indicating that inertial cavitation at
later times and at unwanted locations may play a role in such lesion development. Important
prognosticators for lesion development are the first two imaging time points; from these images,
the shape of the expected lesion can be inferred given the sonication type. If heating evolves from a
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single spot or multiple spots close together, then round
spots are seen, then teardrop or split lesions result.
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Figure 3-6. MRI spatial temperature maps for 5 distinct lesion types. (a) The temperature
evolution of conventional CW ultrasound control exposure. The temperature evolution for a
circular lesion, an oval lesion, a "tadpole" shaped lesion, and a split lesion are shown in (b), (c),
(d), and (e) respectively.
When evaluating the temperature images for different exposure types, another potential
benefit of CE heating was observed. Figure 3-7 shows the T2-weighted images before heating and
temperature maps at the mid point of heating for two sonications. In all images, the X denotes the
thermal focus. The images on the left involve a 420-joule control sonication, and the images on the
right are for a 420-joule type I exposure. In the vicinity of these exposures, there exists
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considerable bone and cartilage tissue in the farfield as well as in planes behind the sonication
plane. Bone tissue, seen as bright regions on the MRI T2-weighted images, can be seen in (a)
above the control sonication location, and the hip joint can be seen in (b) immediately above the
location for the type I sonication. Bone tends to reflect ultrasound and create farfield heating as
shown by the arrow in (c). However, farfield heating is not observed in the type I sonication (d)
which also has bone and cartilage tissue in the farfield. The bubbles generated in the CE heating
exposures seem to shield energy deposition in the farfield throughout the sonication. This farfield
shielding was observed in most but not all CE heating exposures.
(a) (b)
1
8.
U 6
0 A
a 
(c) (d)
Figure 3-7. MRI imaging showing the bubble shielding effect of cavitation. (a) and (b) show the
T2-weighted MR image of the location to be sonicated. Both locations have significant bone or
cartilage tissue in the farfield. (c) and (d) show the respective temperature image. (c) shows
heating of the farfield tissue from bone reflections, while farfield heating is not present in (d).
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3.3.4 Lesion Analysis
In conventional therapeutic ultrasound, round or oval lesions are desired over "teardrop"
shape lesions, and split shaped lesions are undesired. Table 3-2 shows the percentages of these
lesion types, a quantitative representation of the qualitative observations shown in Figure 3-6. The
table shows some general trends. Split lesions do not occur in control, type I or type IV exposures,
and occur in about a quarter to a third of the type II and III exposures. As mentioned previously,
inertial cavitation detected after the 5-second mark indicates the potential of a split lesion, but late
inertial cavitation does not always result in split lesions. "Teardrop" shaped lesions do occur in
type II and III exposures, but are more common in the type I and type IV exposures affecting 11-
18% of the sonications. Skin and nearfield heating percentages are also shown in table 3-2. Skin
and nearfield heating is indicated when a temperature rise greater than 6 degrees C is observed at
the skin or the nearfield in the MRI temperature images. The incidence of nearfield heating in the
CE heating exposures is similar to the equal energy control exposures except in two cases. In the
type II, 560-joule sonication, over 60% of the sonications resulted in skin heating presumably due
to deposition of high intensities in the near field. The type I exposures consistently had lower skin
heating percentages than the equivalent energy control. These type I exposures not only enhance
the therapy but also seem to reduce one primary side effect.
Table 3-2. Lesion Shapes and Side Effects for the Different Sonication Types
Sonication Type % Split Lesions % Teardrop Shape % Skin Heating
Type I
290 J 0.0% 11.1% 6.7%
420 J 0.0% 11.8% 5.9%
560 J 0.0% 18.2% 9.1%
Type II
290 J 27.8% 5.6% 5.6%
420 J 20.0% 6.7% 13.3%
560 J 12.5% 0.0% 62.5%
Type III
290 J 37.5% 0.0% 6.3%
350 J 25.0% 0.0% 12.5%
420 J 35.7% 14.3% 14.3%
Type IV
420 J 0.0% 12.5% 12.5%
Control
290 J 0.0% 0.0% 3.4%
350 J 0.0% 0.0% 11.1%
420 J 0.0% 0.0% 11.1%
560 J 0.0% 0.0% 16.7%
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Figure 3-8 is a T2-weighted image with thermal dose contours of 4 lesions of different
sonications types. All exposures were performed at 420 joules, and the sonication type is shown
below the lesion. In the image, the hottest spot is noted by the X, and the fat tissue, the bright
triangle region is marked on the right side. The image shows that the 240-minute thermal dose
contours agree well with the actual lesion shape as seen with MRI T2-weighted imaging. This
agreement is seen in all lesions (see Figure 3-6 for additional examples); therefore, thermal dose
can be used to predict lesion shape with these sonication protocols. This figure also illustrates the
general trend in lesion size noted with these heating exposures. Lesion C is slightly larger in
volume than A followed by lesion B which is larger than C and then lesion D, the largest. We can
infer from this figure that type I sonications produce the largest lesions, and this is confirmed with
the lesion measurement data. Table 3-3 lists the lesion volume statistics of each CE heating
exposure type relative to its equal energy control. The values were obtained by dividing the lesion
volume of the experimental exposure by the volume of the neighboring control sonication. Type I
sonications produce the largest lesions, yielding lesion sizes 3 to 5 times larger in volume than
equal energy controls. Type II, III, IV sonications yield lesions roughly 2 times larger than the
control exposures. Experimental lesions were smaller than control lesions in only the 560-Joule
type II sonications, and this was due to the high levels of nearfield energy deposition observed in
these exposures. The variability in lesion volumes for the different exposure types was similar
except in the case of the low energy type I exposures. In these exposures, lesion volumes were 3.8
to 8.6 larger than their respective control exposures demonstrating the greatest CE heating benefit.
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Figure 3-8. MR imaging of the lesions generated from 3 different sonication types with the
thermal dose contours overlaid. Note that type I lesions are larger than the type II and III lesions
which are larger than the control.
Table 3-3. Lesion Volumes of Bubble-Enhanced Heating relative to control
Sonication Type Mean Relative Lesion Volume Standard Deviation
Type I
290 J* 5.14 1.70 *Lesions were made
420 J 2.93 0.54 closer to skin to
560 J 3.25 1.08 allow lesionType II 29Type II 1.920formation with
420 J 1.59 0.63 equivalent control420 J 1.59 0.63
560 J 0.85 0.35 exposure.
Type III
290 J 1.99 0.75
350 J 2.06 0.52
420 J 1.56 0.69
Type IV
420 J 2.11 0.41
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3.4 Discussion
The goal of this study was to understand the mechanisms and effects of cavitation-enhanced
heating and to develop control and monitoring techniques for different types of CE heating
exposures. In addition, the best sonication protocol that generated the largest lesion while
minimizing side effects was to be determined. Four general types of CE heating exposures were
studied, and in all sonications, the underlying premise was to induce bubble nucleation in the first
500 milliseconds, and then to follow it with different ultrasound exposures to determine the best
methods for using the seeded gas bubbles. Constant power ultrasound, 2 types of pulsed
ultrasound, or a third exposure in which constant power ultrasound was combined with pulses
followed the cavitation pulse. For all the exposures, the role of inertial cavitation, stable cavitation,
nonlinear heating, and conventional absorption were assessed by examining the acoustic detector
signal. The acoustic phenomena were examined in the context of MRI thermometry, and the
resulting lesion volume measurements served as outcome indicators.
To assess bubble activity, the spectral energies in critical frequency bands were monitored
and recorded. The spectra from the acoustic receiver provided insight into the mechanism of our
CE heating protocols. The 0.4 MHz - 1.0 MHz spectra for sonication types I-III clearly suggest
that all inertial cavitation ceases within the first seven seconds of the exposure; in addition, the
levels of inertial cavitation, if present, are greatly reduced after the initial pulse. This suggests that
inertial cavitation is important in seeding the bubble at the onset of sonication, but it is not
important in maintaining higher levels of heating as MRI thermometry shows rising temperatures
after the termination of inertial cavitation. In addition, the correlation of late exposure cavitation
activity with multi-spot heating and split lesions suggests that inertial cavitation after the initial
seeding is undesirable. Late exposure cavitation in these cases led to significant heating at
locations outside the primary thermal focus, above or below, and irregular lesion shapes resulted.
Thus, the timing of inertial cavitation during an exposure is critical for lesion shape determination.
Type IV sonications' spectra differ greatly from the other exposure types. Their 0-1 MHz spectral
band time profile indicates that inertial cavitation occurs during later pulses. The primary
difference between these sonications and the pulsed sonications (II and III) is the low level of
constant ultrasound between pulses, which seems critical for consistent inertial cavitation at later
times during sonication. The presence of the low level ultrasound seems to reduce the cavitation
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threshold, and therefore pulses that previously did not induce inertial cavitation now do. It is
possible that maintaining an acoustic field allows smaller undetectable bubbles to persist while
completely terminating the field, as is done in the type II and III exposures, extinguishes bubbles.
The presence of these smaller bubbles can then seed inertial cavitation at lower acoustic intensities.
Type IV sonications also produced equal or greater levels of inertial cavitation after the initial
pulse, but unwanted split lesions did not result with these exposures. In addition, despite the
presence of inertial cavitation at later time points, greater temperatures and lesion volume did not
result. The compendium of all this data suggests that there is an optimal balance of energy that
goes into generating cavitation with energy that goes into pure absorption and focal heating. Once
cavitation is generated with a high intensity pulse, higher temperatures and larger lesions are
produced when ultrasound energy is used purely for absorptive heating as in the type I sonication
rather than into generating inertial cavitation as in the type IV sonication. The cavitation spectral
data, temperature data, and the lesion analysis clearly shows that type I sonications produce the
largest lesions while minimizing the side effects.
The spectral energies in the 1.75 - 2.2 MHz band were examined separately to evaluate the
effects of ultraharmonic heating during the sonications. In the type II sonication, a statistically
significant higher level of energy, although less than a third of the initial level, was persistent
throughout the sonication. The type II sonication employs the longest duration of high intensity
ultrasound, so therefore the greatest ultraharmonic energies would be expected from this sonication
type. However, despite the higher levels throughout the sonication, the effects of higher absorption
from ultraharmonics were not significant enough to cause higher temperatures or larger lesions.
Thus, the complete set of ultraharmonic spectral data suggests that ultraharmonic heating plays
little to no role in the enhanced heating seen with experimental exposures. The final piece of the
acoustic receiver signal analysis is the examination of the half-harmonic frequency peak. Although
there is great variation in this value during sonication, values higher than control levels might
suggest that some very limited stable bubble activity is present. This is especially true of the type I
sonication which shows on average greater half-harmonic levels than the control for the first 5-7
seconds. This suggests that bubbles are enhancing the heating during at least a fourth of the
sonication time. Thus, based on the type I sonication result, the optimal cavitation profile is to
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induce inertial cavitation with one burst, and then to maximize the time of stable bubble activity to
enhance the heating for longer times.
MRI spatial and temporal temperature maps also proved valuable in evaluating these
sonications. The temperature versus time curves showed the step response type heating profile
common in all CE heating exposures. This type of heating profile not only provides a higher
thermal dose, but thermal models show that constant temperature produces more uniform spatial
heating than the conventional exponential heating profile (Damianou & Hynynen 1994). This fast
initial heating is also more suitable for MRI thermometry based feedback control of ultrasound
heating (Hutchinson, Dahleh, & Hynynen 1998;Vimeux et al. 1999). The spatial temperature maps
show the different types of lesions that can result from these CE heating exposures. More
importantly, the expected lesion shape can be inferred by examining the first few temperature time
points. If round or oval lesions are to be formed, early temperature images show a single spot or
multiple spots close together. If split lesions are to result, two spot heating is observed in the early
MRI images. Monitoring of these early images is critical to control the lesion shape. If significant
two spot heating is observed early in the exposure, the ultrasound focus location can be adjusted to
prevent "teardrop" or split shapes. In addition, the presence of two spots can serve as an indicator
for the lack of a bubble barrier, which forms near the transducer focal point. The presence of this
gas barrier is probably what limits the farfield heating discussed earlier. Although not directly
observed in this study, the barrier is probably more of a gas pocket than a large concentration of
bubbles and has been observed as streak lines with diagnostic ultrasound imaging (Hynynen
1991b). The spectral data from this study further supports the claim that this barrier is a gas pocket
as no long term inertial or stable cavitation is present. However, the barrier effect is present
throughout the sonication.
The monitoring techniques used in this study can clearly be used to control cavitation
enhanced heating exposures. First, the subharmonic energies during sonication can be used to
assess inertial cavitation, and transducer powers can be adjusted to limit inertial cavitation to the
first few seconds to seed bubbles and to eliminate unwanted cavitation elsewhere in the field.
Second, the half-harmonic energy can be monitored to determine the presence of stable bubble
activity. If higher temperatures are desired, a pulse to induce inertial cavitation could be given
upon on the termination of stable bubble activity. The intensity for this pulse need not be as high
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as the initial pulse, as the type IV cavitation indicates that lower powers and shorter duration pulses
can be used to induce inertial cavitation. Once inertial cavitation is observed in the subharmonic
energy band, the half-harmonic peak could be monitored again and the process repeated if
necessary. And as discussed earlier, evaluation of MRI temperature images can be used to control
lesion shape by adjusting the transducer focus to limit heating in unwanted regions.
In this study we present one technique for cavitation-enhanced heating, but our results
suggest that this approach of initiating cavitation at the onset might be the best method to use
cavitation to enhance thermal therapy. As mentioned in the introduction, some studies have
investigated cavitation-enhanced heating with conventional therapeutic ultrasound but at slightly
higher intensities (Bush, Rivens, ter Haar, & Bamber 1993;Chapelon et al. 1991;Gelet et al.
1996;Sanghvi, Fry, Bihrle, Foster, Phillips, Syrus, Zaitsev, & Hennige 1995). In these exposures,
cavitation does not occur reliably at a given ultrasound power, and if it occurs, it is induced at
some unknown and uncontrollable time during the exposure. In addition lesions formed from these
types of exposures can produce "tadpole" shaped lesions with significant nearfield heating.
Another approach has been to inject gas bubbles, mainly contrast agents, or sonodynamically
active agents into the bloodstream and then follow with conventional therapeutic ultrasound (Tran
& Hall 2000;Umemura & Kawabata 1996b). This approach would lower intensities required for
cavitation, and provide a bubble population for cavitation enhanced heating. But these techniques
also greatly increase the chances of ectopic inertial cavitation since bubbles would be present in
blood vessels everywhere including the nearfield regions which would get repeated exposures with
multiple sonications. Our technique effectively localizes the gas bubbles to the transducer focus
thereby reducing the probability of nearfield or ectopic cavitation.
Some aspects of the current technique and the associated hardware can be improved. One
problem with our CE heating protocols is the high ultrasound acoustic powers needed for inertial
cavitation. However, multi-frequency exposures could be used to enhance rectified diffusion and
therefore lower the cavitation threshold (Umemura & Kawabata 1996b). Transducers capable of
higher intensities at lower frequencies could be used during the initial burst to lower the required
ultrasound powers. Another potential problem was the incidence of non-focal cavitation. Phased
array transducers that could tightly control the overlap of the multi-frequency interaction zone
could further limit the cavitation to the intended regions. In addition, improving time resolution of
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both the cavitation detection and the MRI temperature imaging would allow for faster correction
and better control.
In conclusion, this study has identified possible mechanisms of cavitation enhanced heating
in vivo. It has shown that bubble effects when balanced with sufficient energy for thermal
absorption can reliably be used to augment conventional focused ultrasound therapy by producing
larger lesions that can be predicted with MRI thermal dosimetry. Based on the lesion volume data
and heating profiles, CE heating exposures which follow the initial bubble seeding pulse with
constant level ultrasound worked better as they produced the largest lesions with minimal side
effects. MRI and acoustic monitoring techniques investigated were shown to be effective
mediators for therapy control. Elements of the passive ultrasound cavitation detector signal,
specifically the subharmonic frequency bands and the half-harmonic peak value, could be used to
control the balance of inertial cavitation activity with absorption, and MRI thermometry could used
to control lesion shape. These three parameters could be used in a closed loop control of a more
efficient ultrasound treatment with shorter treatment times, less off-focal heating, and precise
lesion sizes and shapes.
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4 Design of Multi-Frequency Cavitation Fields for Spatial Control of
Cavitation
4.1 Introduction
In the initial chapters of this thesis, the potential utility of cavitation in ultrasound ablative
therapies was demonstrated. However, heating is not the only therapeutic application where gas
bubbles and cavitation show promise. Cavitation has been implicated as the primary mechanism
for a whole host of emerging applications. It is the primary mechanism in the focal opening of the
blood-brain barrier for drug delivery, a technique in which intravascularly injected gas bubbles,
ultrasound contrast agents, are insonified with focused ultrasound (Hynynen et al. 2001b).
Similarly, gene therapy agents in the presence of microbubbles have shown increased transfection
rates into cells when sonicated (Greenleaf, Bolander, Sarkar, Goldring, & Greenleaf 1998;Unger,
McCreery, & Sweitzer 1997). Inertial cavitation is also the primary mechanism for focal drug
delivery via drug carrying microbubbles (Ho et al. 1997;Unger, McCreery, Sweitzer, Caldwell, &
Wu 1998). Anti-tumor drugs, such as Paclitaxel, can be suspended in the oil shell of microbubbles.
Then these bubbles are injected into the bloodstream and locally fragmented to deliver drug to
specific sites limiting systemic toxicity. In other ablation approaches, injected microbubbles rather
than seeded bubbles, as studied in this thesis, have been used to enhance heating (Tran & Hall
2000). All of these techniques have in common the need to precisely control the site of cavitation
for localizing the therapy. Such control is absolutely mandatory in applications with injected
microbubbles. In such situations, the bubbles are present throughout the tissue; therefore, the
likelihood of off-focal inertial cavitation with its associated detrimental effects is much greater. In
some of these applications, inertial cavitation is needed, and in others, stable oscillation of bubbles
is desired. Thus, the type of cavitation also needs to be controlled for optimal therapy. In this
chapter, techniques for localizing cavitation by controlling the acoustic field will be theoretically
investigated.
Several researchers have examined acoustic waveform manipulation methods to suppress or
enhance cavitation at the transducer focus. Chapelon et al. studied the sonoluminescence activity,
the emission of light associated with cavitation, of microbubbles insonified with pseudorandom
phase-modulated signals as compared to continuous wave (CW) single frequency ultrasound
(Chapelon et al. 1996). Their experiments showed a 50 times larger sonoluminescence intensity
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with the single frequency signal when compared to the pseudorandom signal suggesting a possible
cavitation suppressing waveform in the phase-modulated signal. Others have suggested combining
two frequencies in the insonation field to enhance cavitation at the focus. Bailey et. al. combined a
250-kHz continuous wave with 3-MHz pulses at either the positive or negative phase of the lower
frequency wave(Bailey 2002). Their results indicated that superimposing the high frequency pulse
on the positive phase yielded higher cavitation activity. Umemura et al. sum the fundamental and
the first harmonic at the focal point of 2 confocal transducers to study the sum's effect on
sonodynamic therapy, a method where an injected anti-tumor agent is cavitated to treat tumors
(Umemura & Kawabata 1996a). They showed in an in vivo mouse model that the 2 frequencies
when mixed at specific phases enhance the cavitation effect and justified the result with a simple
rectified diffusion model. Of these techniques, Umemura's approach seems to be best suited for
controlling cavitation in therapeutic ultrasound applications, as the mixed frequencies are
therapeutic frequencies of the same order of magnitude. Therefore two-frequency field can be
realized with a single material transducer. In addition, their approach has been validated in vivo,
whereas the other techniques have not been verified in living tissues. Although, Umemura et. al.
show enhancement of cavitation effects, their study does not discuss cavitation threshold and how
it might be related to these dual frequency waveforms. And despite studying the waveforms'
effects on cavitation at the focus, this study and all other studies in the literature on waveform
manipulation for cavitation control, do not study the cavitation properties of the transducer's
acoustic field outside the focal point.
In this study, we develop multi-frequency methods to preferentially lower the cavitation
threshold at the focus relative to the rest of the field for very precise control of the cavitation site
while minimizing off focal, or ectopic, cavitation acitivity. First, 3 families of multi-frequency
driving waveforms are evaluated in a bubble model incorporating rectified diffusion. For each
waveform, the rectified diffusion threshold pressure, the waveform amplitude at which there is a
net influx of gas into the bubble, is used to as the cavitation threshold as suggested by earlier works
(Umemura & Kawabata 1996a). From this analysis, the waveforms that have the lowest threshold
will be considered the optimal waveform for inducing cavitation and the waveforms that have the
highest thresholds optimal for cavitation suppression. Second, the results from the optimal
waveform analysis will be verified by experiment. Finally, the theoretical acoustic fields from an
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8-element sector-vortex transducer that has at its focus the optimal waveforms will be computed
and the cavitation thresholds for other points in the field will be calculated from the bubble model.
The goal of this analysis is to determine how the rest of acoustic field performs in suppressing
cavitation when cavitation is induced at the focus. If these acoustic fields do sufficiently raise the
cavitation threshold outside the focus, multi-frequency phased arrays could be used to precisely
control cavitation location.
4.2 Methods
4.2.1 The bubble model
In order to calculate the cavitation threshold (the rectified diffusion threshold as discussed
earlier) for a given driving waveform a two-step method based on Church's work with rectified
diffusion was used (Church 1988). First, the bubble radius-time curve was computed using the
Keller-Miksis bubble model, and then with the radius-time curve, the rectified diffusion threshold
was calculated using the diffusion equation solutions posed by Eller and Flynn (Eller & Flynn
1965;Keller & Miksis 1980). Their reasonable assumption of negligible diffusion during a single
oscillation, i.e. the assumption that rectified diffusion occurs at a much slower rate than bubble
oscillations, allows the decoupling of these equations.
The Keller-Miksis equation was selected as the model is more accurate than the simpler
Rayleigh-Plesset equation in predicting radius evolution over a large range of initial radii and
acoustic pressure amplitudes. The inclusion of compressibility helps overcome the overestimated
cavitation threshold and convergence problems for larger driving pressure posed by the R-P
equations (Keller & Miksis 1980). The more sophisticated Gilmore equation, which includes time-
varying thermal effects, was not utilized here, as the incremental improvement in bubble dynamics
predictions was not worth the additional computation time necessary for solving those equations.
The Keller-Miksis equation as formulated by Parlitz et. al. was used to model the bubble dynamics
(Parlitz et al. 1990):
l1- R +- 3 h2 i = P(,R,t) R P(,R,t) (4-1)
t c) 2 t 3c) C c) p pc At
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This equation based on experiments with a single bubble in an acoustic field, models the
wall motion, R(t), of a bubble with initial radius, R,, in response to an acoustic driving pressure,
Pa(t). The values of constants as shown table 4-1 in were used (Lauterborn 1976).
Table 4-1. Constants used in the Keller-Miksis Bubble Model
Constant Description Value
Po Hydrostatic Pressure 100 KPa
Pv Vapor Pressure 2330 Pa
c Sound Speed 1500 m/s
a Surface Tension 0.0725 N/m
P# Shear Viscosity of Liquid 0.001 N s/m2
p Liquid Density 998 kg/m3
K Polytropic Exponent 1.33
The model incorporates the following assumptions (Edson 2001):
· The liquid surrounding the bubble is water and infinite in extent
* The water is modeled as a compressible liquid, an improvement over Rayleigh-Plesset
* The fluid is assumed to be Newtonian with surface tension included in the analysis
* A single bubble with initial radius, R0, exists in water at t=-O, prior to any forcing
pressure
* The external ambient or hydrostatic pressure is constant
* The bubble contains gas which obeys the polytropic gas law
* Temperature and pressure have uniform spatial distribution within the bubble
* Only spherical bubble oscillations and collapse occur
* Mass and heat transfer between the bubble and the liquid are neglected
* The forcing pressure field is time-varying
* Shear viscosity and viscous dissipative effects are included
These assumptions are accurate for single bubble cavitation in water. However, cavitation in
biological tissue has some additional complexities not included in this model. Tissue is generally
non-Newtonian due to its viscoeleastic properties. Cavitation in vivo is not necessarily generated
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from a single bubble in an infinite medium, but rather from bubble(s) in compartmentalized tissues.
These differences, however, do not preclude us form using this model. In vivo cavitation initiating
from seed bubbles is a reasonable assumption, and in general these bubbles are allowed some room
to oscillate whether it be in the interstitial space or blood vessels. To reflect the initial seed bubble
radii in tissue, a value of Ro = I n, was used as reported in literature (Church 1988). The model
may not predict absolute cavitation thresholds in tissue, but can be used to compare the effects of
different waveforms on bubble dynamics allowing for relative cavitation thresholds.
Although the bubble dynamics model does not include mass transfer, our use of the Eller and
Flynn rectified diffusion equation incorporates it when calculating the threshold. Their
formulation allows the calculation of the gas flux into the bubble over multiple acoustic cycles
given a periodic solution to the bubble dynamics equation (Eller & Flynn 1965). Their equation,
which represents the time rate of change of the moles of gas, n, in the bubble is shown below:
dn 4 % ( B 1/2 (C A>1 (4-3)d = 4rRoD A + Ro (4-3)dt ;,-t C~ B
with A= 1 dt, (4-4)
T b 
and B 1 I( R dt (4-5)
and Cm =CO[ + Ro (4-6)
In the equation, Ro is the equilibrium or initial radius, D is the diffusion constant, Ci is the
concentration of dissolved gas in the liquid, and Co is the saturation concentration of gas in the
liquid. The gas saturation percentage value of C/Co=0.857 was used to represent an air filled
bubble (Church 1988). A and B are calculated from the solution to the Keller-Miksis equation for a
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given forcing waveform, P(t), where Tb is the period of bubble wall motion, R(t), in steady state.
The period of the bubble wall motion is generally a multiple of the period of the forcing function,
in our case the period of the highest frequency in our multi-frequency waveform. In this work, A
and B were computed for different multiples of this period, 1 to 5, in successive time regions in
steady state of the radius-time curve. When the computed values of A and B over the adjacent
time regions were within 0.1%, those values of A and B were used in the calculation. Next, in
order to determine the rectified diffusion threshold, the pressure at which there is net flux of gas
into the bubble, the zero of equation (4-3) needs to be determined for different amplitudes of the
A Ciforcing pressure waveform. Thus, the pressure at which B = , the zero of equation (4-3), was
noted as the threshold.
In summary, to compute the pressure threshold for a given waveform, the radius-time curve,
R(t), is calculated from the Keller-Miksis Equation with an initial test pressure amplitude. Then, A
and B are computed and compared to C/CS. If the value of A/B is greater than Ci/C, then the
pressure amplitude is raised. If A/B is less than C/C,, then the amplitude is lowered. The process
is repeated until A/B is within 0.1% of C/Cm, and the pressure amplitude used for this result
represented the cavitation threshold for the given waveform.
4.2.2 Tested Multi-frequency waveforms
The cavitation thresholds for three families of driving waveforms were calculated. The first
family of curves was generated from the Fourier decomposition of the ideal waveforms shown in
Figure 4-la. In these curves, the zero crossing within a period of the waveform is varied (from 5
% to 95% of the period) which has the effect of altering the time spent in the positive and negative
phases. Manipulation of the positive and negative phases of the biphasic waveform as represented
with this family of curves has been used to localize the cavitation field in pulsed lithotripters
(Sokolov, Bailey, & Crum 2001). As such waveforms cannot be realized in continuous wave
fields from real transducers, the Fourier series expansion of these waveforms, which utilizes a
discrete set of frequencies, was evaluated. Figure 4-lb shows the waveforms constructed from the
fundamental and first harmonic samples of the Fourier expansion of the waveforms in (a). These
curves have a DC offset, as the DC component of the Fourier expansion is non-zero.
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Unfortunately, DC offsets cannot be realized with acoustic fields from real transducers, so the
offset waveforms were evaluated in our model. Waveforms from this family with 3 frequency
components, fundamental, first harmonic, and second harmonic frequencies were also studied.
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Figure 4-1. (a) Family of curves where the zero crossing of biphasic period waveform is varied
from 5% to 95% of the period. (b) The waveforms shown in (a) with just the fundamental and
first harmonic components of the Fourier expansion of (a).
The second family of curves tested is shown in Figure 4-2a. In these waveforms, the zero
crossing is fixed at 50% of the period, but the maximum and minimum points are varied from 5 %
of the half-period mark to 95% of that time creating curves that look like shock waves as the
percentage approaches 100%. Figure 4-2b shows the dual Fourier component waveform. This
family of waveforms does not have a DC component, so the dual frequency signal more closely
resembles the target waveform, and improves as higher harmonics are added.
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Figure 4-2. (a) Family of curves where the maximum and minimum of a biphasic waveform are
varied from 5% of the half-period to 95% while the zero crossing is kept at 50% of the period.(b) The waveforms shown in (a) constructed with just the fundamental and first harmonic
components of the Fourier expansion of (a).
The final set of waveforms evaluated were the sum of two equal amplitude but different
frequency cosines, P,,(0.5cos(2irft) +0.5cos(2nr2ft + )), where 0 was varied from 0 to 360°.
Figure 4-3 shows the waveform shapes for a subset of this family for 5 different values of 0. These
waveforms bear a strong resembles to the first family of curves except that these waveforms are the
sum of equal amplitude sinusoids where in the first family, the amplitudes are scaled by the Fourier
magnitude components.
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Figure 4-3. Family of curves calculated from Pac (0.5 cos(2rfit) + 0.5 cos(27r2ft + 9)), where 0 is
varied for 0 to 2.
4.2.3 Experimental Verification of Theoretical Results
The waveform family that produced the greatest variation in cavitation thresholds as the
varying parameter was altered was thought to be optimal, as bubble forcing with such waveforms
would yield the greatest threshold difference for cavitation suppression versus cavitation
enhancement. Once the optimal waveform family was selected, the threshold variation observed in
simulation was verified experimentally. Figure 4-4 shows the experimental setup for measuring
cavitation threshold for different dual frequency waveforms. An 8-element sector-vortex
transducer (Imasonic SA, Besancon, France) driven by a multi-channel broadband ultrasound
driving system (described in the next thesis chapter) was used generate the dual frequency field in
a water tank. The focus of the transducer was positioned to be in the center of a 2.5 cm diameter X
2.5 cm long cylindrical vial containing a mixture of degassed water and OptisonTM (Mallinckrodt
Medical, St. Louis, MO), a commercial microbubble contrast agent. The plastic cylindrical vial
was capped on both ends with mylar membranes to allow the passage of the ultrasound beam
through the chamber. A concentration of 0.15 mL of OptisonTM for every 10 mL of water, the
dilution used in in vivo imaging applications, was maintained in the vial. To ensure that no large
air bubbles were trapped in the chamber, the microbubble mixture was circulated into the vial until
liquid was observed on the outflow line. Prior to sonication, the cylindrical vessel was slightly
agitated to keep microbubbles in suspension. To detect cavitation during insonation, the
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transducer's center circular element, the 9 element, was connected to a spectrum analyzer
(Hewlett-Packard 8590A) and used as a passive cavitation detector. Similar to earlier in vivo
experiments, the presence of broadband subharmonic emission was used access inertial cavitation.
For each waveform tested, the input voltage was raised until inertial cavitation was observed. The
driving voltage is linearly proportional to the driving pressure, so the voltage level at which inertial
cavitation is observed is proportional to the threshold pressure. On a final note, OptisonTM has a
mean bubble size of 2-4.5 rpm, so the results from experiment were compared with simulation
results with Ro in this range.
flow
OptisonTM
Syringe
Cylindrical
Vial
Cavitation
Water Tank Detector
Figure 4-4. Experimental setup for measuring cavitation threshold for multi-frequency
waveforms.
4.2.4 Acoustic Field and Cavitation Field Calculations
In this thesis, we introduce the concept of the cavitation field. The cavitation field is defined
as the relative cavitation threshold in space for a given acoustic field. From the acoustic field, the
pressure waveform in each point in space is known, and this pressure waveform can be used to
compute the cavitation threshold using the model described earlier. If the acoustic field is a single
frequency field, the cavitation field is constant as the waveform is constant and only varies in
amplitude and phase. However, if the field is multi-frequency in nature, different waveforms exist
in space so different cavitation thresholds will result in space. Thus, the cavitation field is
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dependent on the transducer geometry and the specific excitation of the transducer, i.e., the driving
signal to each element of the transducer. For this study, we compute the cavitation field for an 8-
element sector vortex array with multi-frequency excitations. For all dual frequency fields,
alternating elements were driven at the two different frequencies. Multi-frequency excitations,
which were simulated in the first part of this simulation study, were used to design cavitation fields
that have a lower cavitation threshold at the focus relative to the rest of the field.
The acoustic field for the transducer was numerically calculated using the Rayleigh-
Sommerfield integral (Zemanek 1971). The pressure field from an ultrasound element through a
lossy substrate can be modeled as:
ipck e- ik(r-r )e-dU (1)
p(r) = ZPCk r-dA (1)
where Po is the tissue density, c is the speed of sound, k is the wavenumber (27/L), X is the
ultrasonic wavelength, r is the coordinate vector (x,y,z) of the pressure point, r'is the coordinate
vector of the incremental source area of the complete transducer area A, u is the attenuation
coefficient in the lossy material (absorption and scattering), d is the ray distance in the lossy
material between the source point and the location of the desired pressure point, and u is the
complex surface velocity of that source (magnitude and phase). For an array with N elements, the
pressure at a given point m corresponding to a location (Xm, y, Zm) is given by:Pm - d 
where subscript n corresponds to the driving signal of the nth element of the array. This model
neglects temperature, non-linear, refraction, and scattering effects on pressure calculation and for
our purposes, the absorption and scattering, the attenuation term, was also neglected. This integral
computes the complex pressure for a single frequency field. Thus, the 8-elment array was modeled
as 2 separate arrays for dual frequency excitation, and the resulting fields were summed in the time
domain using P cos(2rfit + 1)+P 2 cos(2zrf2t +02), where PI and 9O are the magnitude and angle
of the complex pressure atfi and P2 and 2 are magnitude and angle of the complex pressure atf2 .
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With the time-varying field in space, the cavitation threshold at various points can be computed
using the model described earlier.
4.3 Results
4.3.1 Relative Cavitation Thresholdsfor Various Families of Pressure Waveforms
Figure 4-5 shows the relative cavitation threshold for the first family of curves, the dual
frequency waveforms in which the zero crossing is varied from 5% of the period to 95% of the
period. The different curves present the threshold variation for waveforms of different periods.
For example, the 1.2 MHz curve represents a waveform constructed with 1.2 MHz and 2.4 MHz
sinusoids and has a fundamental period of (1.2 MHz)- ' , and the 2.4 MHz curve shows the result
from combining 2.4 MHz and 4.8 MHz sinusoids and so on. For waveforms with a fundamental
frequency of 1.2 to 2.4 MHz, waveforms with a lower zero crossing point exhibit a lower threshold
with the minimum threshold occurring at zero crossing of 0.5. Two important observations can be
made regarding these trends. At these lower fundamental frequencies, pressure waveforms that
have a higher peak minimum pressure than the peak maximum pressure (as seen in Figure 4-1)
have lower thresholds, about 1.10 times the minimum threshold pressure as compared to1.55 times.
Second, waveforms that approach the true sinusoid, zero crossing equal to 0.5, exhibit the lowest
threshold. At this zero crossing value, the contribution from the first harmonic is almost zero
whereas at zero crossings equal to 0.2 and 0.8, the first harmonic amplitude is 1/3 of the
fundamentals contribution. Thus, if we generated a transducer field with a zero crossing of 0.5 at
the focus, we should suspect that the cavitation field will be relatively uniform as one frequency
dominates the acoustic field. However, if we selected the waveform with zero crossing of 0.2, a
variable cavitation field would result with a lower threshold at the focus. The other important
aspect of these graphs is the reversal in trends for frequencies in the 2.7 MHz to 4.0 MHz range.
The reversal is probably related to the bubble resonance frequency, which is roughly 3.0 MHz for a
1-micron bubble. Most of the curves in the second graph are above the bubble resonance, so for
these frequencies, waveforms with later zero crossing that exhibit longer negative phase (as seen in
Figure 4-1) exhibit a lower threshold. The difference in threshold across the range of zero
crossings is similar to the lower frequency curves with the exception of 2.7 and 4.0 MHz, as these
fundamental frequencies exhibit very little difference between low and high values of zero
crossing.
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Figure 4-6 shows the effect of approximating the same biphasic waveform family with 3
frequencies of the Fourier series, the fundamental, first and second harmonic. The addition of the
3 rd harmonic component creates a larger cavitation threshold difference (1.1 versus 1.9) between
waveforms with low zero crossing (0.2) and those with high zero crossing points (0.8). At zero
crossings of 0.2 and 0.8 the relative amplitudes of the fundamental, first harmonic, and the second
harmonic are 0.65, 0.22, and 0.13 respectively, and a more differential cavitation field might result
as the fundamental contributes less than in the 2 frequency case.
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Figure 4-5. Relative cavitation threshold for the first family of curves where the zero crossing
point of the biphasic waveform is varied from 5 to 95% of the fundamental period. The results
are shown for various fundamental frequencies ranging from 1.2 to 4.0 MHz.
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Figure 4-6. Relative cavitation threshold for the first waveform family when the waveforms are
represented using 2 and 3 frequencies of the Fourier series. A fundamental frequency of 1.2
MHz was used.
Figure 4-7 shows the relative cavitation threshold for the second family of curves in which
the zero crossing is fixed at 0.5 of the period, but the point of the minimum is varied from 5% of
the half-period to 95% of the half-period which creates a shock like waveform seen in Figure 4-2.
This waveform family does not show a significant cavitation threshold differential for waveforms
that have significant first harmonic amplitudes, pressure minimum points less than 0.3 and greater
than 0.7. Again the minimum threshold occurs when the first harmonic contribution is nearly zero,
so these waveforms cannot really be used create a differential cavitation field.
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Figure 4-7. Relative Cavitation Threshold for the second family of curves where the zero
crossing is fixed at half the period but the minimum and maximum points of the biphasic
waveform are varied from 5 to 95% of the half-period. The results are shown for two
fundamental frequencies.
As the previous two families of curves employ relatively low contributions from the first
harmonic frequency, a waveform family in which equal amplitudes of the fundamental and first
harmonic frequencies was also studied. The relative cavitation threshold for such waveforms with
the phase of the first harmonic varied from 0 to 3600 is shown in Figure 4-8. For lower
fundamental frequencies, 1.2 to 2.4 MHz, the waveforms show a differential in the cavitation
threshold with the first harmonic phase of 200° degrees showing the lowest threshold. Again
similar to the first curve family, the trend is reversed for frequencies at or above bubble resonance
frequency with the lower threshold observed when there is no phase delay for the second
harmonic. The results are consistent with the first waveform family as the curve shapes are similar
(when comparing Figure 4-1 and Figure 4-3) with primary differences due to the equal amplitudes
of the two combined frequencies. This waveform family is probably a better candidate for creating
a differential cavitation field as the equal amplitude sinusoids combining at various phases in the
field will create a more widely varying acoustic field. Whether the differential field can be
exploited by preferentially lowering the threshold at the focus and raising the threshold elsewhere
will be discussed later.
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Figure 4-8. Relative Cavitation Threshold for the third family of curves where equal amplitude
sinusoids of the fundamental and first harmonic are combined with the first harmonic having a
variable phase delay.
4.3.2 Experimental Validation of Relative Cavitation Thresholds
To verify the reliability of our cavitation threshold model, the results from experiments with
OptisonTM were compared with predictions from our simulations. For the water tank experiments,
the OptisonTM sample was insonified with the focal pressure profile generated from the third
waveform family, the combination of equal amplitude sinusoids with the phase delay of the first
harmonic varied. Figure 4-9 shows the results of the experiment with simulations from bubble
radii of 1 to 4 micron, a representative set as the mean radius of the OptisonTM microbubbles are
between 2 and 4 micron. The experimental data follows the model results from the 2 and 3 micron
bubble very closely. Not only are the trends consistent, but the minimum and maximum relative
cavitation thresholds are almost identical. The predictions from the model correlate very well with
the predictions from the controlled experiment, and therefore, general trends predicted by these
models are most likely accurate to the first order. On a separate note, this figure also shows a trend
for increasing bubble size. As the initial bubble radius is increased a greater cavitation threshold
differential is observed within the waveform family for different first harmonic phases. The trend
of lower thresholds near 1800 and higher thresholds near 0° is invariant to bubble size, so we can
probably assume that the cavitation field will behave similarly for various initial bubble sizes.
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Figure 4-9. Relative cavitation thresholds for dual-frequency equal amplitude excitation where
the phase of the second harmonic is varied for various values of Ro with the data from
experiments with OptisonT M overlaid.
4.3.3 Cavitation Fields Generatedfiom Multi-Frequency Acoustic Fields
As the data from Figure 4-5, Figure 4-6, and Figure 4-8 suggest, there is a clear cavitation
threshold difference between waveforms within waveform families one and three. Therefore
logically, fields could be designed such that a waveform with a lower threshold occurs at the focus
and waveforms with higher thresholds result in other areas of the field. To study the effectiveness
of this technique, the cavitation field for the 8-element sector-vortex array was simulated with 3
different multi-frequency excitation patterns taken from the previously discussed results. Figure
4-10 shows the theoretical acoustic and cavitation fields when the family 1 waveform with zero-
crossing of 0.2 is delivered at the focus Figure 4-10a shows the acoustic field pattern of the peak
pressures normalized by the peak pressure at the focus. The orientation of the field is such that the
transducer would be to the left of the graph. The full-width-half-maximum dimensions of the
focus are about 1.1 mm wide by 5.5 mm long, which is smaller than the 1.2 MHz single frequency
focus (not shown) that measures 1.3 mm by 6.5 mm. Just with the dual frequency acoustic field,
we have gained some additional cavitation control by simply reducing the focal size. Figure 4-10b
shows the cavitation field along the x-axis of the acoustic field in the focal plane normalized to the
minimum value of the cavitation threshold in the graph. The plot shows a relative threshold at the
focus of almost 1.1, a value 10% greater than the minimum value which occur closest to the focus
at +/-0.05 mm and also at later points away from the focus. However, as we move away from the
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focus the cavitation threshold reaches a maximum value of close to 1.3 at +/-0.9 mm meaning that
pressures 20% greater than the pressure found at the focus are needed to cavitate at these locations.
These maxima essentially bound the potential cavitation region along the x-axis. Additional
minima in the threshold occur at periodic intervals outside the maxima where the nodes of the high
frequency field are present. At these points the low frequency field dominates giving a lower
cavitation threshold. Cavitation is unlikely to occur at these points, as the fast drop off of the
acoustic intensity limits these areas to very low pressure levels as compared to the focus. Figure 4-
10 Oc shows the relative cavitation threshold along the axis of the transducer. Again similar to what
was observed along x-axis, 2 peaks in the cavitation threshold surround a region of low cavitation
threshold at the focus. These peaks also have the effect of bounding the focus. Most off-focal
cavitation occurs along this dimension in the near field of the transducer, and the threshold
maximum would limit cavitation from occurring in the near field up to -6 mm (point where the
threshold is same as at the focus) from the focus.
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Figure 4-10. Acoustic and cavitation fields of a dual-frequency ultrasound exposure aimed at
generating a lower cavitation threshold at the focus using a waveform from the first waveform
family. (a) The acoustic field near the focus oriented with the focus to the left. (b) The
cavitation field along the x-axis in the focal plane. (c) The cavitation field along the transducer
axis.
As the 3-frequency version of the first waveform family showed greater threshold
differentials, the cavitation field for this waveform was also simulated. Figure 4-11 shows the
acoustic and cavitation fields in the case where 3 frequencies are combined to yield the 0.2- zero-
crossing waveform at the focus. The acoustic field plot seen in Figure 4-1 la shows a full-width-
half-maximum size of 1 mm x 4.5mm, so adding the third frequency reduces the focus size.
However, the cavitation field pattern is less advantageous than the 2-frequency case. Along the x-
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axis, very little threshold differentials are observed. There are 2 maxima, but their regions are too
small to be very effective is suppressing cavitation outside the focus. The y-axis threshold profile
is improved with the maxima broad enough to suppress cavitation immediately out the focus, but
this region is not as large as in the 2-frequency case.
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Figure 4-11. Acoustic and Cavitation fields of a triple-frequency ultrasound exposure aimed at
generating a lower cavitation threshold at the focus using a waveform from the first waveform
family. (a) The acoustic field near the focus oriented with the transducer to the left. (b) The
cavitation field along the x-axis in the focal plane. (c) The cavitation field along the transducer
axis.
The graphs shown in Figure 4-12 are the field patterns resulting from combining two equal
amplitude sinusoids with the first harmonic signal having a phase of 2100 at the focus. This phase
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angle exhibited the lowest cavitation threshold among the family 3 waveforms. The focal size as
measured from Figure 4-12a is 0.9 mm x 4.4 mm, the smallest focus thus far. The cavitation field
from this waveform family is also the most promising. Figure 4-12b shows larger threshold
maxima surrounding the focus with a maximum threshold value 50% larger than at the focus.
Figure 4-12c shows similarly high maxima along the axis of the transducer, in addition, a higher
threshold in the nearfield than at the focus is observed for the entire nearfield region shown in the
plot and continues beyond. To cavitate in the nearfield, pressures ranging from 110% to 150% of
the pressure at the focus is needed. To see if greater differentials can be obtained, other waveforms
from the same family with different first harmonic phases were evaluated, and among the best
nearfield to focal point threshold differentials resulted from the pattern with first harmonic phase
angle of 233 °. The focus from this field has similar dimensions to the other waveform from family
three, and x-axis cavitation field is also not too remarkably different. However, the cavitation field
along the axis of the transducer shown in Figure 4-13 shows significant improvement over the
previous field. The cavitation threshold in the nearfield ranges from 117% to 153% of the
threshold at the focus with a space-averaged threshold of nearly 122% of the threshold at the focus.
This differential is a significant improvement over a single frequency field which exhibits a
uniform cavitation field. To cavitate in the nearfield, 48% higher intensities (intensity and power
vary as pressure squared) than that found at the focus is needed assuming a homogenous media.
Tissue is not homogeneous; however, significant tissue factors that lower the threshold in the
nearfield would be needed to overcome this higher threshold barrier. Larger bubbles near the
resonance size (in our case 3 micron) might act as threshold reducing factors, but at these bubble
radii the cavitation threshold differential is maintained (see Figure 4-9) with this waveform family,
and higher pressures (as compared with a single frequency field) would still be needed for
cavitation.
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Figure 4-12. Acoustic and Cavitation fields of a dual-frequency equal amplitude ultrasound
exposure aimed at generating a lower cavitation threshold at the focus using a waveform from
the third waveform family. (a) The acoustic field near the focus oriented with the transducer to
the left. (b) The cavitation field along the x-axis in the focal plane. (c) The cavitation field along
the transducer axis.
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Figure 4-13. The cavitation field along the transducer axis from an equal amplitude dual-
frequency exposure optimized to generate a large threshold difference between the focus and the
nearfield.
4.4 Conclusions
In this chapter, a method to evaluate the cavitation field of an ultrasound transducer with a
known excitation pattern is introduced. The technique involves 2 basic steps: first, the acoustic
field for a given transducer with known excitation pattern is either theoretically calculated or
experimentally measured, and then the cavitation threshold is calculated in space using the time-
domain acoustic field as the input pressure excitation to a bubble model incorporating rectified
diffusion. In this study, the Rayleigh-Sommerfield Integral was used to calculate the theoretical
acoustic field and the Keller-Miksis bubble model with Flynn's rectified diffusion equation was
used to predict cavitation threshold. These equations combine to provide an excellent first order
representation of the cavitation field; however, there are clear limitations to the theory. First, the
cavitation field that we calculate assumes a fixed initial bubble radius for the entire field, that is,
we assume that the seeding bubble size is 1 micron throughout the field. In reality, bubbles of
various sizes might be present in the field especially if vasculature and tissue interfaces are present.
However, trends within one waveform family for various bubble radii (Figure 4-9) showed that the
relative cavitation field is relatively invariant to different bubble radii despite the variability of the
absolute pressure threshold. In addition, the constant bubble radius assumption is an accurate
representation of therapy techniques with injected bubbles as the bubble radii fit a tight
distribution. Second, multi-bubble effects as well as the effects of gas saturation were not
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modeled. Third, our model assumes a homogenous medium, water, which is clearly not
representative of inhomogeneous tissue. However, Keller-Miksis equations have been verified to
make reasonable predictions of bubble activity in tissue-mimicking materials for large amplitude
ultrasound excitations (Holt & Roy 2001). Lastly, the acoustic wave propagation is assumed to be
linear, so phase aberration effects in the field as well as the generation of harmonics are neglected.
Despite these limitations, our model of the cavitation field correlated well with controlled in vitro
experiments predicting the magnitude of the relative cavitation threshold as well as the general
trend for one waveform family.
In addition to providing an experimentally tested methodology for calculating the cavitation
field, our model was used to test the cavitation control capabilities of a basic 8-element sector-
vortex transducer. Multi-frequency excitations with this transducer were investigated to develop
ultrasound excitation profiles that would preferentially lower the cavitation threshold at the focus
relative to other regions in space, specifically the axial nearfield of the transducer. We successfully
showed that with this simple phased array, multi-frequency excitations could be used to generate
fields where the cavitation threshold pressure in the nearfield is 20% greater than at the focus.
Although the predicted cavitation threshold fields remain to be validated by experiment, the initial
demonstration shows enormous potential for multi-frequency cavitation field control. The
cavitation fields developed could be used to tightly control the site of cavitation near tissue
interfaces, blood vessels, or fat which might exhibit lower thresholds and induce unwanted
cavitation in the nearfield of the transducer. This result was obtained by a single parameter
optimization: the goal was to lower the threshold at the focus and then see if the threshold
elsewhere was higher. Based on the cavitation threshold differential observed with the various
waveform families, a differential threshold was expected, but the exact spatial distribution was not
known. To find the best cavitation field for a given application, a multi-parameter optimization
could be performed. The cavitation threshold at the focus, or any other point, could be
preferentially lowered compared to other specified points in the field, and the remainder of the
field could be simulated. These specified points might be vital anatomical structures where
cavitation and it is associated damage is to be avoided. To do this optimization, the cavitation
threshold would be computed for all the test points for a family of excitation waveforms, the
waveform that yielded the greatest differential would then be used. The techniques presented
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here would allow for the development of such control. With the high degree of field control
afforded by broadband phased arrays, these simulated and uniquely designed cavitation fields
would be realizable for virtually any anatomy and application.
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5 Design and Evaluation of Broadband Multi-Channel Ultrasound Driving
System for Large Scale Therapeutic Phased Arrays
5.1 Introduction
Therapeutic ultrasound phased arrays show great promise in the treatment of brain disorders
and deep-seated tumors where precise beam steering and controlled power deposition are needed
(Clement et al. 2000b;Daum et al. 1999b). In addition, cavitation and mechanical effects, which
are fast becoming essential elements of these therapies, could be potentially better controlled with
phased array systems that employ multi-frequency techniques (Chapelon, Dupenloup, Cohen, &
Lenz 1996;Umemura & Kawabata 1996a). However, these recent therapeutic ultrasound
applications increase the demands on the phased array hardware both the ultrasound transducer and
the multi-channel electronic driving system. First, large scale (greater than 200 elements), high-
density (elements on the order of X/2), broadband ultrasound phased array transducers capable of
generating high power fields are required. Second, multi-channel amplifier systems that are
capable of fully utilizing these large scale, high-density, broadband arrays needs to be developed.
With the advent of high power piezocomposites (Gururaja, Newnham, Klicker, Schulze, Shrout, &
Bowen 1980;Shrout, Bowen, & Schulze 1980), broadband high-density transducers are now
available for therapy; however, the current driving system technology still falls short. In this
chapter, we describe the design, construction, and evaluation for a multi-channel broadband phased
array amplifier system capable of driving large scale therapeutic phased arrays.
5.2 Methods
5.2.1 Therapeutic Piezocomposite Transducer Arrays
Before considering the design requirements for the next generation ultrasound driving
system, it is important to understand the load, namely the ultrasound transducers. Till recently, the
majority of therapeutic ultrasound arrays have been fabricated from the PZT as these materials
have high electro-acoustic efficiency. Piezocomposites, in their brief history, have been used
mainly in medical diagnostic applications. However in the past half-decade, two companies have
begun to fabricate 1-3 composite piezoelectric materials for high power applications (Materials
Systems, Littleton, MA and Imasonic SA, Besancon, France). These materials have been
extensively studied and characterized in our laboratory (Daum 1998;Raymond 2002)
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demonstrating the earlier described advantages for therapeutic applications. Since these early
studies, transducers fabricated by Imasonic have been used to demonstrate the feasibility of liver
and transcranial brain treatment. Daum et al. showed in porcine model, that 256-element etched
electrode piezocomposite transducer driven by multi-channel switching amplifier could be used to
ablate liver tissue (Daum, Smith, King, & Hynynen 1999b). Clement et al. have shown that a
320-element piezocomposite hemisphere array can be used to steer a coherent beam into the brain
for ultrasound therapy (Clement & Hynynen 2002). These applications still do not demonstrate the
full capabilities of piezocomposite as multi-frequency therapy with phased arrays for the
controlling the cavitation field remains to be experimentally demonstrated.
In this study, the newly constructed ultrasound driving system will be tested with 2 1-3
piezocomposite transducers to demonstrate the full capabilities of both the phased arrays and the
ultrasound driving system. An 8-element sector-vortex piezocomposite array (diameter = 10 cm, f
= 0.8, and multiple resonances at 1.2 and 2.4 MHz) and 24-element cylindrically curved linear 1.1
MHz array (radius of curvature = 40 mm, element length = 30 mm, and X/2 element width) both
made by Imasonic will be used to demonstrate the capabilities of a broadband phased array system
for ultrasound therapy. Although, the driving system is designed for the piezocomposite arrays, we
expect the new system to drive ultrasound phased arrays made from any material.
5.2.2 Design Requirements for Large Scale Multi-channel Broadband Ultrasound Driving
System
To bring broadband large scale phased array therapy to fruition, the next generation phased
array driving system must address the following criteria. First, the amplifiers must have a broader
frequency range than that afforded by switching amplifier designs. Therapeutic ultrasound
frequencies range from 0.5 MHz to about 5 MHz, so in our design we would like to operate
comfortably beyond this bandwidth and extend our capabilities to the 0.1-10 MHz range. Second,
in order to fully realize multi-frequency therapy, we would like to drive each element of the phased
array with a unique arbitrary waveform, potentially non-sinusoidal, in our prescribed frequency
range. Third, the waveforms must have sufficient time and amplitude resolution to not only phase
elements but also to apodize (amplitude shading of individual elements) the phased array. Fourth,
the amplifier stage must provide sufficient power to make ablation feasible with large scale (1000+
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elements) phased arrays. We estimate that operation in the 0.5-1.5 electrical watt range depending
on the frequency and the number of elements would provide adequate power for many therapeutic
applications. Fifth, techniques for avoiding or simplifying electrical impedance matching of
phased array elements to amplifier channels, an absolute necessity with switching amplifier
designs, need to be developed. And lastly, the cost of electronics per channel in addition to the size
of the electronics per channel must be small enough to make very large scale (1000+ elements)
phased array driving systems feasible. Our design aims to be low cost and compact. Essentially,
these design requirements force us to trade off the more expensive, more efficient, high power
switching amplifier topology which was ideal for driving high Q small scale phased arrays with for
a cheaper, broader band, lower power, circuit topology which is better suited for driving large scale
broadband phased arrays. This circuit topology is introduced below.
5.2.3 The Ultrasound Driving System
Figure 5-1 shows a schematic representation of the broadband ultrasound driving system
design. The system consists of 3 primary component sets: 1) the PC with a high-speed digital I/O
board used to control the amplifier system and transmit digital waveform data to a custom-design
printed circuit board (PCB) which holds the other 2 component sets; 2) the digital arbitrary
waveform generation circuitry which translates the received binary data into low current analog
signal; and 3) the analog components which filter and amplify the arbitrary waveforms for each
channel. Components shown in the shaded region of the figure represent circuitry that is repeated
for every channel.
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Figure 5-1. Block diagram of the Ultrasound Driving System. The shaded region highlights the
circuitry that repeat for each channel.
5.2.3.1 Controlling PC and Digital I/O Board
To control the amplifier system, a Microsoft Windows based PC was installed with the NI
PCI-6534 (National Instruments, Austin, Texas), an 80 Mbytes/second data transfer rate, 32-bit
digital I/O board. The I/O board is controlled through a Visual Basic 6.0 program via a DLL
library supplied by the board manufacturer. For the purposes of our design, the board was
programmed to simulate a high-speed 32-bit parallel port. In this mode, 32 lines of binary data can
be simultaneously transmitted to our amplifier board at 20 MHz if the 80 Mbytes/s maximum
transfer rate was used. Of the 32 data bus lines, 16 bits serve as true data lines for transmitting
waveform values, etc. This bus will be hereon referred to as the 16-bit data bus to distinguish this
subset from the 32-bit data bus. The other 16 bits are used as control lines for selecting different
components on the board for programming and manipulation and for higher-level functions such as
powering on and off the amplifiers. The I/O board is the only master on the 32-bit bus; there are
no PCB components such as microcontrollers or transceivers that can take control of the bus
greatly simplifying the digital circuitry and programming.
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5.2.3.2 Digital' Circuitry
Figure 5-1 highlights the 5 major components of the digital circuitry: the waveform memory,
the address counters, the address counter memory, the waveform D/A converter (DAC), and the
reference voltage D/A converter. All of these components and their associated support components
are laid out on the PCB. The waveform memory, a 64K x16 bit static RAM for each channel,
stores the waveform sample values. Although the selected memories are capable of 16-bit words,
only 10-bits are used providing us with 1024 levels of vertical resolution for our output waveforms.
These values are directly loaded into each channel's memory via the 16-bit data bus. The
individual memories are selected for programming via the control bus and digital decoder
components not shown in the figure and are programmed one channel at time. The address
counters assist in the programming of the waveform memories; they supply the rolling memory
addresses at 20 MHz as the data is put on the 16-bit data bus. The waveform memories of all the
channels are addressed by one set of address counters and their memories; this single addressing
technique ensuring synchronization between all outputs. The address counter memories serve to
provide preload values to the counter for loading waveforms at different addresses in memory.
Once the waveform memories are programmed with the desired output waveforms, all 3 of the
major components we have discussed so far are used to provide the 10-bit data to the D/A
converters during the running stage. The D/A converter is the central component of the digital
arbitrary waveform generation circuitry. It converts the 10-bit word seen at its input to an analog
waveform with a dynamic range of 0 to 1 volt. The D/A selected for our design is that fastest
commercially available DAC on the market running at up to 65 MHz. During the running or
output phase, the clock to the address counters and the DAC are switched to a 65 MHz oscillator to
allow for greater time resolution. At 65 MHz, waveform samples are read out every 15.4
nanoseconds, providing the capability for phase resolution of 5.5 degrees or 65 steps at 1 MHz, 11
degrees or 32 steps at 2 MHz, and so on. Each DAC also has individually wired power down lines,
so selected DACs can turned off for random array applications. The last component highlighted in
the schematic is the reference voltage DAC. This DAC and associated latch is used to set the
reference voltage for all the waveform DACs, so the total power level of the array can be adjusted
in real time during the output phase.
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5.2.3.3 Digital Control
For simplicity and expandability reasons, the amplifier boards are controlled by a parallel
port style architecture. Control of electronics via serial port, USB, and microcontrollers were also
investigated, but direct parallel control of all digital electronics was eventually selected.
Microcontroller based designs require both low-level programming of the microcontroller in
addition to higher-level programming to control the microcontroller and provide a user interface. In
addition, component level busing architectures, such as I2C, are needed to fully utilize the data
checking and two-way communication benefits afforded by microcontroller design. Such busing
schemes not only limit the component selection, but also increase cost. In addition, such busing
schemes would provide very little benefit in our application where only one way communication
between the controller and components are needed. Although USB or serial port interfacing
would have made the board more controllable with any PC, direct control of all electronics would
not be possible therefore making timed control more difficult.
For the purpose of control, the board was treated as a finite state machine. Via an external
PC control, the board can be placed in a finite set of states as shown in Figure 5-2. And from any
given state, only a finite set of operations can lead to a state change. Each operation or instruction
is coded with a specific 16-bit word that is used to directly control the components, and 16-bit data
argument can be sent when is required by any component. Table 5-1 shows the main operational
states of our amplifier board and some of the instructions. The table below describes each state. In
the figure, "memory write" refers to programming any of the memories, and memory read refers to
the memories, either the counter or waveform memories, outputting the stored data to the counter
or the DACs respectively.
The amplifier boards are controlled via the digital I/O card through a Visual Basic 6.0 user
interface. This custom designed graphical user interface (GUI) essentially translates high level
user inputs into a series of instructions which are then sent to the amplifier board. The user
interface allows waveform programming via 3 mechanisms. In the simplest scheme, all channels
can be driven at single frequency and at an overall output voltage level. Prior to output, individual
channels may be enabled or disabled. In a more versatile input mode, a file containing the channel
number, the frequency, the phase, and the relative voltage level for each channel may be loaded
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into the GUI and the amplifier board with then be subsequently programmed. The most versatile
mode allows a file specifying the exact digital waveform values for each channel to be loaded and
programmed. With any of the programming methods, the timing of the ultrasound exposure, i.e
the length of time the output is enable, can be specified form the number of cycles to number of
seconds or minutes. This initial GUI provides most of the features essential for therapy.
Preload Counterwith Memory
Write or Read Start Address
Finished Loading PD Latch
Channel 1
Finished Preloading Counter
Read Start Address
enable
Figure 5-2. The Digital Control State diagram. Each circle represents a distinct state of the
amplifiers with the processes that can change the state indicated by the arrows.
Table 5-1. Amplifier Board State Descriptions
State
Standby
Preload Counter
Memory Write
Memory Loaded Standby
PD Latch Load
Output On
Description
The state the electronics assume on power up.
This state effectively sets the starting address for memory
writing or memory reading.
The state in which the memory modules are being
programmed.
The standby state when all relevant memories are loaded
and ready for output.
This state refers to the loading of the power down latches
which essential turn off/on the DAC for a given channel.
State in which the memories are put in a read state and an
analog signal is delivered to the load.
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5.2.3.4 Analog Circuitry
As shown in Figure 5-1, the final stage of the ultrasound driving system design is the analog
electronics. The analog output signal of the D/A converter is filtered and amplified by a series of
Operational Amplifier circuits as shown in Figure 5-3. The first Op-Amp circuit applies a voltage
gain of 11 to the DAC output signal augmenting the voltage swing to 0 to 11 volts. In addition,
running an Op-Amp at high gain can reduce the bandwidth significantly effectively converting it to
a low pass filter as well. The resulting low pass cutoff frequency for our circuit was higher than
our desired output frequency range but lower than the quantization noise frequency of 65 MHz, so
the first Op-Amp stage also filters out the clock and quantization noise. The signal is then high
pass filtered with a simple first order Resistor-Capacitor (RC) circuit to remove the DC offset
yielding a signal with voltage swing of -5.5 Volts to 5.5 Volts. In the final stage, the signal's
current is amplified with a high power Op-Amp; this Op-Amp circuit also provides a voltage gain
of 2 resulting in a final high current (up to 150 mA) signal with a maximum peak-to-peak voltage
swing of 22 volts.
Figure 5-3. Circuit topology of the analog components of the amplifier system. The first Op-
Amp circuit provides the voltage gain, and the second Op-Amp provides the high current output.
5.2.3.5 Printed Circuit Board and Other Design Considerations
All digital and analog electronics described above were incorporated on to multi-layer
custom-designed printed circuit board (photo shown in Figure 5-4). This PCB was designed with
well-established guidelines from literature for mixed signal (analog and digital electronics) circuits
(Montrose 2000). The guidelines suggest techniques for isolating analog and digital electronics to
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reduce interference, methods for ground plane design for optimal signal grounding, and techniques
for reducing electromagnetic interfere among many other details. Special attention was paid to a
few other design considerations. To minimize power requirements for the digital electronics, 3.3 V
CMOS technology were exclusively used for all digital components. For all components, both
analog and digital, the smallest surface mount packaging was used to minimize the surface area
required per channel. In the final board design, 50 channels of the amplifier were fabricated onto
230 mm x 400 mm PCB, based on the 6U VME board size standard, with per channel electronics
confined to an area of 25 square centimeters. In addition to component size, cost was also factored
into component selection resulting in $20 per channel cost for the 50 channel board. The 50 high
current outputs of the board were cabled via coax to DL connectors (ITT Canon, Santa Clara, CA)
for easy connection to phased array transducers. Several sets of these 50 channel boards can then
be run in parallel under the control of one PC and one master clock to drive large scale phased
arrays. Regarding the master clock, clock lines to the DACs of all channels were laid out to be
very close in length as to minimize delays in the output between channels on the board. As long
the clock lines supplying the boards are equal in length and adequate in current, any number of
boards can be combined to drive very large scale arrays.
Figure 5-4. Photograph of the 50-channel ultrasound driving system board.
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5.2.3.6 Transducer Driving Issues
In previous therapeutic phased array driving system designs, phased array elements were
matched to the output of the amplifiers to ensure maximum electrical power transfer. Matching is
extremely important in switching amplifier designs as the circuit relies on resonance of the
switching amplifier to be matched with the resonance of the load. It is critical to high efficiency
DC to AC conversion performed by these types of amplifiers. With our previous amplifier (Daum
et. al. 1998), each element of the transducer was hand matched via a second order Inductor-
Capacitor (LC) circuit with the assistance of an impedance meter. The arduous process of hand
matching for large scale phased arrays would be extremely time consuming and would limit large
scale phased arrays to niche applications. In addition, matching is typically done at a particularly
frequency, so the multi-frequency therapy techniques could not be utilized.
Our Op-Amp circuit topology is less efficient than switching amplifier designs, but that drop
in efficiency is traded off for two very important benefits: 1) the Op-Amp via feedback and its
internal active electronics locks the signal at the output to the signal at input (essentially the DAC
output) and maintains the signal at the desired voltage at the load; 2) broadband signals can be
passed on to the Op-Amp and these high bandwidth signals with amplification will be delivered to
the load. The first feature virtually eliminates the need for matching provided that the elements'
impedances are in a prescribed range, and the second feature makes broadband therapy feasible.
In order to determine if matching is need for a given transducer, the maximum attainable
power from the transducer must be computed. To make this calculation, the transducer's electrical
impedance over the operating frequency range must be measured. From the impedances, the
maximum electrical power attainable per element can be computed as the maximum current and
voltage attainable by our circuit topology is known. If electrical power requirements for a given
application fall within the attainable power levels, matching is not need. Figure 5-5 shows the
theoretical maximum current and maximum power versus load impedance for our amplifier
specifications. The maximum real rms current versus the load impedance is simply calculated by
taking the real part of the maximum root mean square (rms) voltage, which is no greater than 7.78
volts (the rms value for a sinusoid with a peak-to-peak voltage of 22 Volts), divided by the
complex impedance, Z. The maximum power is next calculated using the following equation,
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P_ = ReV. maxIms m*)=R{Vs /Z = Re{I2rms maZ},
with V_, no greater than 7.78 Volts and Iis_max being no greater than 150 mA. From these
plots we can see that the maximum power attainable per channel is a little greater than 1 watt. If
the load impedance is between 50-60 Ohms in magnitude and between +/- 25 degrees in phase, 1
watt or greater can be achieved per channel. The maximum power falls off much faster with lower
impedances than with high impedances. This drop-off is a result of the current limits of the Op-
Amp as with lower impedances, higher currents are required for higher powers. In our laboratory,
most piezocomposite transducers for therapy have impedances ranging from 30-200 Ohms in
magnitude with a phase range of +/- 85 degrees with higher density arrays with smaller elements
having larger impedances. With 500-element phased arrays, this allows for total electric power of
100 to 500 watts (assuming 0.2 to 1 watts per element) that is sufficient for most therapeutic
applications.
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Figure 5-5. (a) Theoretical maximum current delivered to the load, the transducer, for know
complex transducer impedance. The maximum current deliverable to the transducer is 150 mA.(b) Theoretical maximum power deliverable to the transducer given its complex transducer
impedance. The maximum power is about 1.2 Watts.
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5.2. 4 Evaluation of Multi-channel Ultrasound Driving System
The performance of the broadband ultrasound driving system was characterized through a
series of electrical and acoustic experiments. For these test, 2 different amplifier boards were used.
The first amplifier board, developed initially for electrical design testing utilized the full PCB
design but included components for only 8 channels. The second board made use of the same
PCB, but components for all 50 channels were soldered to the board. Both boards performed
identically, so they were used interchangeably except for testing that required more than 8
channels.
5.2.4.1 Electrical Testing
In the first electrical test, the bandwidth of the driving system was characterized. For these
measurements, sinusoidal inputs at varying frequencies were loaded into four channels of the
amplifier board and the channels were programmed to output the maximum voltage. All channels
were connected to individual 50-Ohm loads (Bird Electronic Corp., Cleveland, OH). The amplifier
theoretically delivers some of the highest powers at this load impedance level (Figure 5-5),
therefore, representing a true characteristic of the maximum bandwidth. The 50-Ohm load was
driven over a frequency range of 0.1 MHz to 20 MHz and the maximum voltage delivered to load
at each frequency was measured. The peak-to-peak voltages of all channels were measured
simultaneously on a Yokogawa DL7100 digital oscilloscope (Yokogawa Electric Corp., Tokyo,
Japan) with averaged acquisitions, and the electrical power was calculated for the given load.
These powers were then plotted versus frequency to represent the amplifier system electrical
bandwidth.
In the second electrical test, the electrical efficiency, of the 50-channel amplifier system was
measured. For all measurements, the 50-channel board was driven by 3 separate laboratory DC
power supplies with digital current and voltage displays each supplying the 3 voltages need for
board operation. The digital 3.3 Volts was supplied by the Sorensen DCS 40-25 power supply
(Sorensen Company, Chicago, IL) that is capable of delivering up to 25 Amps. The voltage
sensing capabilities of the power supply were utilized to maintain 3.3 volts at the board, as the high
current demands resulted in a significant voltage drop across the power delivery lines. The 5 volts
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needed for the counters and DAC analog section were supplied by the 2-Amp Tektronix PS280
(Tektronix Inc., Wilsonville, OR) and the 3-Amp Tenma 72-6615 (Tenma Test Equipment,
Springboro, OH) supplied the +15 Volts for the Op-Amps. For the power demand measurements,
the amplifier board was driven at maximum output voltage with each channel driving individual
50-Ohm loads at 1.0 MHz. The supply voltages and currents were recorded in standby mode (the
system power is on but the outputs are disabled) and in the maximum power mode described
above. As current demands of 50 channel operation exceed the specifications of the power
supplies used, the measurements were taken for 40-channel operation and then extrapolated for 50-
channels. These power measurements not only help gauge the electrical efficiency of the driving
system, but will aid in final power supply development for multiple board operation.
5.2.4.2 Acoustic Testing
In addition to assessing the electrical capabilities of the amplifier system, the ultrasound
driving capabilities of the multi-channel system were evaluated with the two piezocomposite
transducers described earlier. Acoustic power and acoustic efficiency measurements were taken
while driving the 8-element sector-vortex array. Prior to driving the array, the complex electrical
impedance of all elements of the array was measured with the Hewlett-Packard 4195A Spectrum
Analyzer (Yokogawa-Hewlett-Packard Ltd., Tokyo, Japan) over the frequency range of 0.5 to 4
MHz. All elements of the transducer array were directly connected to the amplifier system without
matching and driven at maximum voltage with sinusoids from 1 to 2.6 MHz. The peak-to-peak
voltage at each frequency was measured as described earlier and the input electrical power was
calculated using the previously measured transducer impedances. The transducer was positioned
in a degassed water tank and radiation force techniques were used to measure the resulting acoustic
power at each frequency (Stewart 1982). With these acoustic and electrical power measurements
the acoustic efficiency of the transducer-amplifier system was calculated.
Finally, the acoustic field capabilities of the broadband amplifier-piezocomposite array
system were assessed. The two arrays were driven with various excitations and the resulting
acoustic fields were characterized. The transducers were positioned in a degassed water tank with
ultrasound absorbing rubber lining, and their acoustic fields were scanned with a Precision
Acoustic 0.075 mm hydrophone (Precision Acosutics Ltd., Dorset, England) attached to a
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computer controlled three dimensional positioner (Velmex Inc., Bloomfield, NY). The positioner
was moved in steps of 0.1 or 0.2 mm to scan the acoustic field. The acoustic signal from the
hydrophone was captured on a Tektronix TDS3012 digital oscilloscope (Tektronix Inc.,
Wilsonville, OR), and transferred to the PC via GPIB (General Purpose Interface Bus, IEEE 488.2)
in between hydrophone movements. Both 1-D and 2-D scans of the transducers' fields around the
focal point were performed. The 8 element sector vortex array was driven in both continuous and
pulsed modes with 3 distinct field patterns. First, the transducer was driven in mode 0 and mode 4
at two frequencies, 1.2 and 2.4 MHz to illustrate simple phased fields. Next, two frequencies, 1.2
and 2.4 MHz, were used to drive alternating elements of the transducer. The 24-element linear
array was driven at 1.1 MHz and focused at two different locations to examine more clearly the
precise phase control afforded by the amplifier system.
5.3 Results
5.3.1 Electrical Measurements
Figure 5-6 shows the maximum power per channel delivered to a 50-Ohm load across a
frequency range of 0.1 to 20 MHz. The actual 4-channel average measurements are indicated by
the solid dots, and a polynomial interpolation was used to generate the curve. The voltage
measurements of all 4 channels were virtually identical for all frequencies, with the roughly 1%
variation resulting from the resolution limits of the oscilloscope. The plot shows that the 1.15
watts per channel can be achieved till about 1 MHz at which point the curve begins to drop off.
The half-maximum power of 0.575 watts occurs between 6-7 MHz, and undistorted sinusoidal
signal at roughly 10% of the maximum power can be observed till about 17.5 MHz. Beyond 20
MHz, the signal becomes largely distorted due to digital undersampling as each cycle is sampled
by roughly 3 points. In the early component selection phase, the bandwidth of the analog
components was tested with an external clock, and the high current Op-Amp was able to maintain
an undistorted, albeit, low power (5 mW on 50 £Q load), sinusoid till about 65 MHz. Thus, the
bandwidth of the complete driving system is limited by the digital sampling rate.
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Figure 5-6. The maximum power versus frequency per channel measured with a 50-Ohms load.
The actual measurements, representing 4-channel average are indicated by the points on the curve.
Table 5-2 lists the power consumption numbers for the ultrasound driving system in 3
different operational states. In the Standby mode, when the digital electronics are powered, the
memories are in a standby state, and the Op-Amps are in a biased state, the board consumes
roughly 30 watts of electrical power. This is the maximum power that can be achieved in this
mode as components for all 50 channels are powered on. The second set of figures in the table
shows the recorded measured power values when 40 channels are each driving a 50-Ohm load. In
this state roughly 120 watts is consumed and a maximum of 46 watts of out power is generated.
The output power is calculated by multiplying the number of channels by 1.15 watts, the maximum
attainable power at 50 Ohms. Based on these numbers, the 40-channel operation yields a total
electrical efficiency of 39%, and if the input digital power is removed, the analog components
operate at 47% efficiency under 50-Ohm conditions. When examining the +/-15 Volt supplies, we
can see that about 0.5 Amps are used in the standby mode for the biasing the Op-Amps, and the
rest is used for power generation. If the currents required for biasing are subtracted from the
currents during operation, the incremental current requirements per channel can be computed.
Roughly 65 mA per channel are consumed from each of the +/-15 volts. With these numbers, the
expected current and power consumption for full 50-channel operation can be calculated. In 50-
channel operation, roughly 125 watts are needed to supply the amplifier board, and if optimal loads
are used, analog efficiencies as high as 54% can be achieved. The 125 watt represents the
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maximum power consumption of the board, and when driving multiple boards, the power
requirements are excepted to increase at a this rate of 125 Watts per board.
Table 5-2. Power Consumption and Electrical Efficiency of the Driving System
Supply Voltage Standby 40 Channels ON 50 Channels ON
Vdc Id Pin Idc Pin Idc Pin
3.3 Volts 4.2 13.9 6.30 20.8 6.3 20.8
+15 Volts 0.46 6.9 3.07 46.1 3.3 49.5
-15 Volts 0.43 6.5 2.95 44.3 3.2 48
5 Volts 0.24 1.2 1.48 7.4 1.5 7.4
Input Power (Watts) 28.5 118.6 125.7
Output Power (W) 46 57.5
Electrical Efficiency 39% 46%
Analog Efficiency 47% 54%
5.3.2 Acoustic Measurements
Figure 5-7 highlights the electrical and acoustic power capabilities of the amplifier system
when driving a transducer. For these measurements the 8-element sector vortex array was used,
and Figure 5-7a shows the average complex electrical impedance of the transducer elements versus
frequency for this transducer. The vertical lines on the curves show the standard deviation of the 8
element measurements. The transducer is complex load, with magnitudes ranging from 10-40
Ohms and the phase ranging from about -60 degrees, a capacitive load, to about 40 degrees,
representing an inductive load. Thus, measurements with this transducer should be representative
of the driving systems capabilities of driving not only an acoustically active load, but also a
complex load. Figure 5-7b shows the maximum electric power deliverable to a transducer
element, the resulting acoustic power as measured by radiation force, and the calculated acoustic
efficiency. As a first observation, a maximum electrical power of roughly 1.15 watts, was
generated at 1.2 MHz, where the transducer elements have an average impedance of 35 Ohms, -20
degrees phase. Upon closer examination, the electrical power curve follows closely the electrical
impedance magnitude curve. At low impedances, less than 30 Ohms, which occurs between 1.4
and 2.2 MHz, less than 0.3 watts was delivered to the load, and when impedances rise again
despite becoming an inductive load, electrical powers close to 1 watt was reached. These trends
correlate well with the theoretical maximum powers shown in Figure 5-5. The acoustic power
curve illustrates that the amplifier system can provide sufficient currents to drive the transducer
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generating acoustic powers as high as 0.72 Watts per element. The acoustic efficiency curve
shows the broadband nature of the transducer, as over the frequency range of 1 to 2.4 MHz,
roughly 30% of the input electrical power is converted to acoustic power.
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Figure 5-7. Electrical impedance and driving performance for the 8-element sector-vortex array.
Plot (a): average electrical impedance, magnitude and phase, of all elements of in the array. Plot
(b): maximum electrical power, acoustic power, and the acoustic efficiency per element versus
frequency.
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The acoustic field capabilities of the driving system were assessed with the 8-element array
and the 24-element linear transducer. These two arrays were driven with various waveforms and
the acoustic field plots below highlight some of the core capabilities of the driving system. Figure
5-8 demonstrates the amplifier's ability to phase arrays. Figure 5-8a shows the acoustic field scan
of the mode 4 phasing scheme (alternate elements are driven 180 degrees out of phase) with the
sector-vortex array driven at 1.2 MHz. For these plots, the Fourier Transform of the acoustic
signal from each point in the scanned space was computed. Then the magnitude at the driving
frequency was plotted versus the 2Dspace. The scan is taken at the focus in the plane parallel to
the transducer face, and the acoustic field is as expected with the 8 spot focus. As the sector vortex
is already geometrically focused, the linear 24-element was phased to demonstrate beam steering
capabilities. Figure 5-8b and c show the acoustic field in a plane 4 cm from the transducer driven
with two different phasing schemes. Figure 5-8b shows the field when the array is phased to a
depth of 4 cm at the center of its aperture, and Figure 5-8c shows the field when the transducer is
focused 7 mm off the axis. The size and shape of the focus is maintained when steering off axis,
and only the expected side lobes can be observed outside the main focal point. The individual
phases to each channel were measured on the oscilloscope and the output phases where within 6
degrees of the assigned phase profile for all elements. Focusing with these transducers
demonstrate the driving systems ability to keep the assigned waveforms synchronized all the way
to the load.
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Figure 5-8. (a) Acoustic field scan of the mode 4 phasing scheme with the sector-vortex array
driven at 1.2 MHz. (b) Acoustic field of the 24-element transducer when the array is phased to a
depth of 4 cm at the center of its aperture and (c) when the transducer is focused 7 mm of the
axis.
Figure 5-9 shows the acoustic field resulting when the 8-element array is excited at two
different frequencies, 1.2 and 2.4 MHz. The frequency combination was chosen intentionally as
summing of these frequencies can yield waveforms that can have different peak negative and
positive amplitudes that are potentially useful in cavitation therapy (Umemura & Kawabata
1996a). Figure 5-9a shows the measured signal at the output of 2 channels of the amplifier system
as they are driving the transducer. These two waveforms excite alternating elements of the
transducer with 4 elements being driven at each frequency. The amplitude of the higher intensity
higher frequency focus was reduced so that equal pressures of the two frequencies result at the
focus. The result of such an excitation is the acoustic pressure waveform at the focus shown in
Figure 5-9b. The acoustic signal is exactly as expected if equal pressure amplitudes of the two
frequencies where summed at the exact phasing shown in Figure 5-9b. Alternatively, if phase
between the two frequencies were adjusted, an exact opposite of this waveform with greater peak
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positive pressures can be generated. Figure 5-9c and d show the acoustic field around the focal
point in the focal plane and in a orthogonal plane along the transducer axis. For these plots, the
peak positive amplitude of the acoustic signal at the given point is summed with peak negative
value. Thus, if the signal acquired at a given point has a higher peak negative pressure than peak
positive pressure, a negative value would be displayed on the plot, and visa versa, a positive value
would be displayed if the peak positive pressure was greater. The figures clearly show the region
with a greater peak negative pressure at the focus. In the focal plane, the dual frequency region
with greater negative pressures is roughly 1 mm in diameter and its size is on the order of the
higher frequency's wavelength. In the axial plane the extent of the greater peak negative pressure
is longer, close to 5mm, and is dependent on the f-number of the transducer. The figures also show
the regions immediately adjacent to the focal point to be areas with greater positive pressures. This
acoustic field data illustrates that the driving system can generated continuous wave multi-
frequency acoustic fields with a single piezocomposite phased array.
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Figure 5-9. Dual frequency continuous wave excitation. (a) Measured signal at the output of 2
channels of the amplifier system as they are driving the 8-element transducer. These two
waveforms excite alternating elements of the transducer with 4 elements being driven at each
frequency. The amplitude of the higher frequency is reduced so that equal pressures of the two
frequencies result at the focus. (b) Acoustic pressure waveform at the focus resulting from such
an excitation. (c) Acoustic field around the focal point in the focal plane and (d) in an orthogonal
plane along the transducer axis.
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The final set of figures show the pulsing features of the amplifier system. Two types of
pulses were generated with the 8-element array. The first was a single cycle pulse at 1.2 MHz that
is shown in Figure 5-10. Figure 5-10a shows the voltage signal delivered to the transducer and (b)
shows the recorded acoustical signal at the focus. Figure 5-10c shows the frequency spectrum of
the acoustic signal at points along the axis of the transducer just before and after the focus. The
single cycle excitation yields a broadband acoustic focus with frequencies from 0.8 to 2.2 MHz, the
bandwidth of the transducer. Figure 5-11 shows a second excitation where a dual frequency pulse
is generated with the phased array. To generate the field shown in Figure 5-1 c alternative
elements of the 8-sector array were excited with the driving system signals shown (a). The result
of this excitation is the acoustic signal shown in (b) at the focus, and the axial field shown in (c).
The dual frequency pulse extends the bandwidth to 2.6 MHz, and also yields a pressure field with
greater peak negative pressures at the focus. As would be expected, the higher frequency
excitation region is smaller than the lower frequency excited region due to its smaller wavelength.
These pulses clearly demonstrate the driving systems ability to generate pulses on the order of
single cycles without amplifier ringing (Figure 5-10a) and also show that multi-frequency pulsed
fields limited only by the transducer's bandwidth can be created with the driving system. In
addition, the pulse data demonstrates the arbitrary waveform capabilities of the driving system.
Pulses of different shapes and duty cycles can be constructed with the driving system.
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Figure 5-10. Single Pulse Generation. (a) Voltage signal delivered to the transducer. (b)
Recorded acoustical signal at the focus. (c) Frequency spectrum of the acoustic signal at points
along the axis of the transducer just before and after the focus. The spectrum magnitude was
normalized to the maximum value and 10 contour levels in increments of 0.1 are displayed in the
figure.
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Figure 5-11. Dual Frequency Pulse at the focus. (a) Voltage signal delivered to the transducer.
(b) Recorded acoustical signal at the focus. (c) Frequency spectrum of the acoustic signal at
points along the axis of the transducer just before and after the focus.
5.4 Discussion
In this study, we have designed, constructed, and tested a broadband multi-channel
ultrasound driving system for large scale phased arrays. The system developed represents a
significant advance for phased array therapy as it incorporates the following feature set. First, the
amplifier can drive transducers in the DC to 10 MHz frequency range. The wide operating range
allows for many therapeutic applications: the sub-megahertz range is used to drive transcranial
ultrasound arrays; extracorporeal applicators for the liver and fibroids operate in the low megahertz
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range; and intracavitary or catheter based ultrasound arrays will exploit the higher end frequency
range. In addition, multi-frequency therapy with phased arrays for cavitation control applications
as suggested in the previous chapter is now possible. The broadband arbitrary excitation capability
will also serve as a powerful research tool for emerging therapies. Outside the therapy arena, the
broadband transmission capabilities can be used for imaging. The frequency range and the
arbitrary waveform capabilities allow for almost all types of ultrasound imaging transmits
including coded-excitations, a new imaging technique recently shown to increase the Signal-to-
Noise ratio in imaging (Pedersen, Misaridis, & Jensen 2003). The second major feature of this
design is the ability to drive piezocomposite and PZT arrays at up to 1 watt of electrical power per
channel without electrical impedance matching. This greatly reduces cost and complexity as
matching networks unique to each element are not required. Of course, if transducer impedances
are high (magnitudes greater than 150 ohms), some non-lossy electrical impedance reduction is
needed. However, the amplifier can drive elements with a broad range of impedances so
impedance reduction would be significantly simpler as compared with previous switching designs
that require tight 50-ohm matching. Third, the design presented here is flexible and easily
updateable. As technology advances, faster DACs and higher power Op-Amps are developed, the
design can be very simply altered to extend the frequency range or to increase the power
capabilities. Indeed, if higher power is needed, this design can be easily modified to use currently
available parts to provide tens of watts of power per channel for a higher cost per channel. Fourth,
the compact design and low cost, less than $20 per channel, allow for effective scaling of this
design to thousands of channels for driving large scale phased arrays. Phased arrays show
enormous potential in therapy: they allow for precise ablation; they make transcranial therapy
possible; they allow for large volume ablation, and with frequency control show great promise for
spatial and temporal control of cavitation. This design effectively moves large scale ultrasound
phased arrays from a theoretical vision to a realizable system for optimal therapy control and opens
the door to the development of new applications.
6 Conclusions and recommendations for future work
6.1 Conclusions
Throughout the history of therapeutic ultrasound, there has been a long-standing debate on
which ultrasound mediated mechanism, temperature or cavitation, is best for in vivo therapy. Over
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the last decade, temperature techniques have been used almost exclusively in clinical therapy
owing to their predictability, controllability, and relative safety. However, cavitation based
ultrasound therapies such as targeted drug delivery and gene therapy are showing promise as
therapies of the future. In addition, researchers are beginning to understand the potential
synergistic relationship that cavitation may play in thermal therapies. Cavitation based ultrasound
therapies are mounting a strong resurgence, yet bubble activity in tissue is still poorly understood
and controlled. This lack of control and understanding essentially limits the clinical development
of these therapies.
The fist goal of this thesis was to exploit the synergistic relationship between cavitation and
thermal effects to develop an optimal cavitation aided heating therapy that would improve on
conventional ultrasound heating techniques. In the process, mechanisms for lesion formation in
vivo were also studied. The result was our cavitation-enhanced heating protocol that seeds inertial
cavitation with a high intensity pulse and follows with lower power ultrasound that capitalizes on
the enhanced absorption provided by the seeded bubbles. These exposures yielded lesions 3 times
larger in volume for equal input energy with reduced side effects from nearfield heating. In
addition to developing the optimal cavitation-enhanced heating therapy, the study also investigated
methods to monitor and control the therapy. MRI and passive cavitation detection were
successfully used to monitor cavitation-enhanced heating in vivo. MR thermal imaging and
dosimetry showed the evolution of the lesion and predicted the eventual lesion size and shape, and
the passive cavitation detector spectrum indicated the presence or absence of bubble acitivity and
the type of cavitation, stable or inertial. These monitoring tools showed that best results, the
largest lesions of regular shape with minimal side effects, occurred when inertial cavitation was
confined to the first few seconds followed by an extended period of stable bubble activity. This
correlation of lesion progression with MR temperature imaging and the passive cavitation detector
spectrum also established potential strategies for controlling the therapy.
The second broader goal of this thesis was to develop methods to better control cavitation in
vivo. Such techniques and tools could be used for all cavitation-based techniques, not just for the
cavitation-enhanced heating protocols developed earlier. Multi-frequency techniques that
selectively lower the cavitation threshold at the focus relative to other locations were introduced
and verified experimentally. By creating this cavitation threshold differential in the insonified
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field, the site of cavitation can be more precisely controlled. Cavitation is more likely to occur in
regions where the threshold is low and less likely to occur in areas where the threshold is high. If
such techniques can be demonstrated in vivo, they would have a impact on cavitation therapy.
Acoustic fields that selectively cavitate at the focus but inhibit cavitation at critical anatomical sites
in the nearfield would tremendously help the entry of cavitation-based techniques into the clinic.
In the final phase of this work, ultrasound hardware, particularly the phased array ultrasound
driving system, needed to implement the multi-frequency cavitation control technique was
developed. The driving system was designed not only for cavitation control techniques but also to
advance the field of phased array ultrasound therapy. The result was a multi-channel broadband
phased array system capable of delivering up to 1 watt of electrical power with arbitrary
waveforms in the DC to 10 MHz frequency range with little or no impedance matching. The cost
and size of the electronics permit simple scaling of the phased array system to thousands of
channels; a significant advance in phased array therapy that now permits very sophisticated
acoustic and cavitation field control. The research conducted through the course of this thesis will
hopefully help bring the important cavitation-based therapies into the clinic.
6.2 Recommendations for future work
This thesis introduces new concepts in cavitation-based ultrasound therapy, but significant
work remains before these concepts can be practically implemented. The animal studies showed
the feasibility and potential benefits of our cavitation-enhanced heating exposures; however,
further study is needed before the technique can be applied to tumors. In our studies, only MRI
was used to assess the lesions post-exposure. Histology of the cavitation-enhanced heating
exposures is needed to accurately define the boundaries and to verify the outcomes observed with
MR imaging. Histology is also needed to classify the type of tissue damage. If coagulative
necrosis is the primary mechanism, we can more definitively conclude that lesion formation is
primarily temperature related. Another unknown in these animal experiments was the spatial
extent of cavitation. With the cavitation detector signal, we were able to identify when cavitation
was occurring, but not necessarily where. Two methods could be used to study the spatial profile
of cavitation. Histology might show regions of bubble acitivity within the lesion post mortem on
the micron scale; whereas, ultrasound imaging during heating would allow real-time monitoring of
the spatial extent of cavitation but with resolution on the millimeter scale. If histology shows clear
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lesion boundaries with uniform necrosis and if the spatial extent of cavitation is appropriately
confined to the lesion, the technique then should be tested in tumor models. Such studies are
required to insure that our cavitation-enhanced heating exposures do not create metastatic disease
and successfully destroy the targeted tumor tissue. Improvements to the technique could also be
made. Although we were able to generate very high peak pressures to seed cavitation, such
pressures might be more difficult in deeper tissues or in situations where lower gain transducers are
used. Three techniques could be explored to reduce the cavitation threshold for the initial
cavitation burst: 1) multi-frequency techniques aimed at lowering the cavitation threshold, 2)
insonification with sonodynamically active agents in the field that have been shown to lower the
cavitation threshold (Umemura & Kawabata 1996b), and 3) insonification with microbubbles
(Tran & Hall 2000). If these techniques are successful in lowering the pressures needed for
cavitation, cavitation field control techniques developed in this thesis could be used to minimize
cavitation outside the targeted focal region.
The theoretical model established in this thesis showed agreement with experiment for one
specific case. That study showed that multi-frequency waveforms could be used to create
differential cavitation fields. Further experimental validation in need. The differential field
predicted by the model for the 8-element sector vortex array should be verified. An in vitro study
(similar to the one conducted in this thesis) where the relative cavitation threshold is measured in
different regions of the field should provide an experimental check of the theoretical result. If in
vitro validation is successful, the results should then be verified in tissue. After experimental
validation, the model could be used to generate differential cavitation fields that inhibit cavitation
at specific locations in the nearfield or fields that might lower the threshold at multiple locations.
We only studied single point control, but this type of multi-point control is possible with phased
arrays. Simulation and optimization of such fields would show the true potential of this technique
for cavitation control.
Finally, work also remains for the ultrasound hardware developed in this study. Broad range
of robustness testing is needed to remove hardware bugs. These tests are currently underway. In
addition, more user-friendly software that simplifies driving system control needs to be developed.
Hardware improvements are also in progress. The backplane essential for interconnecting multiple
50-channel boards to build a large scale driving system is currently being developed. And,
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electronics to add power monitoring and receiving capabilities to a subset of channels is also being
investigated. Impedance reduction techniques, ways to reduce the impedance seen by the
amplifier, also need to be explored. One approach is a simple inductor-capacitor network that
would reduce the load impedance to levels in the optimal range of our driving system. This
approach could provide impedance reduction over a broad range of frequencies allowing for higher
powers.
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